



STOP HIV/AIDS Semi-Annual Monitoring Report

S2 (July 1, 2015 – December 31, 2015)

Ellen Demlow¹, Tim Chu¹, Dr. Reka Gustafson², Dr. Jat Sandhu¹ ¹Public Health Surveillance Unit ²Communicable Disease Control

Final Version: May 17, 2016



Foreword

The Seek and Treat for Optimal Prevention (STOP) of HIV/AIDS Project was a 3 year pilot (Feb 2010 – Mar 2013) funded by the British Columbia Ministry of Health to expand HIV testing, treatment and support with the goal of reducing HIV transmission in British Columbia. The pilot project was implemented in Vancouver and Prince George. Funding was provided to Vancouver Coastal Health (VCH), Providence Health Care (PHC), Northern Health (NH), the Provincial Health Services Authority (PHSA), and the British Columbia Centre for Excellence in HIV/AIDS (BCCfE). The pilot project was successfully implemented in Vancouver over the 3 year pilot period and achieved the project goals to:

- Reduce the number of new HIV/AIDS diagnoses in Vancouver (in the long term).
- Reduce the impact of HIV/AIDS through effective screening and early detection.
- Ensure timely access to high quality and safe HIV/AIDS care and treatment.
- Improve the patient experience in every step of the HIV/AIDS journey.
- Demonstrate system and cost optimization.

Following the successful implementation as a pilot project, the B.C. government announced a provincial roll out of the initiative from April 1, 2013.

The provincial project goals are to:

- Reduce the number of new HIV infections in B.C.
- Improve the quality, effectiveness, and reach of HIV prevention services.
- Increase early diagnosis of HIV.
- Reduce AIDS cases and HIV-related mortality.

Provincial level monitoring and evaluation is being conducted by the BCCfE using provincial testing data from the BC Centre for Disease Control (BCCDC) and provincial treatment data from the provincial drug treatment program at the BCCfE. Quarterly population level indicator reports are produced by the BCCDC and BCCfE for monitoring and evaluation purposes.

During the pilot, the Vancouver STOP HIV/AIDS Project *Quarterly Monitoring Report* was developed to enable VCH and PHC (Vancouver STOP partners) to report on overall changes in the project's targeted activities and display results at a population level within Vancouver Health Service Delivery Area (HSDA) and across VCH. This report provided important information to support timely and informed decision regarding project implementation, resource allocation and post-project sustainability planning.

With the expansion, we will continue to monitor the key indicators across VCH. The *Semi-Annual Monitoring Report* will provide the output to support informed decision making, and inform internal and external stakeholder groups about the VCH STOP project's impacts.

Please note the data sources used for this report are of a dynamic nature, and are subject to change on a frequent basis. Definitions of some indicators are also subject to change in order to meet the evaluation needs of the regional stakeholders. Please refer to Appendix A and consult the most recent report for the most up to date definitions. If you have any comments and queries, please forward them to Tim Chu (tim.chu@vch.ca) or Ellen Demlow (ellen.demlow@vch.ca).

Table of Contents

Acknowle	dgements	5
Table of A	Abbreviations	6
Caution/In	iterpretations	7
Section 1	Population Monitoring Report Overview	9
Population	a Level Monitoring Indicators	10
Summary	Table Results	12
Monitorin	g Indicators Summary Table	15
Section 2	Testing Indicators - Graphs, Maps and Tables	19
Figure 1	Number and Percent Positivity of POC tests	23
Table 1	Number of HIV Lab Tests by HSDA/LHA of Testing Clinic	24
Map 1	Mean Monthly HIV Lab Tests per 10,000 population by LHA – Historical Period	25
Map 2	Mean Monthly HIV Lab Tests per 10,000 population by LHA – STOP Pilot Period	25
Map 3	Mean Monthly HIV Lab Tests per 10,000 population by LHA – Stop Expansion	25
Figure 2	Number and Percent Positivity of HIV Lab Tests among VCH Residents	26
Figure 3	Number and Percent Positivity of HIV Lab Tests among VCH Residents by HSDA	27
Table 2	Monthly Average of HIV Lab Tests, Population Rate of Lab Tests, Positives and Percent Positives among VCH Residents by HSDA/LHA	28
Table 3	Percent Positivity of HIV Lab Tests among Vancouver Residents by Gender and Age Group	29
Table 4	Percent Positivity of HIV Lab Tests among Rest of VCH Residents by Gender and Age Group	30
Figure 4	Proportion of New HIV Positives by Gender and Males/Females Ratio by Year of Diagnosis	31
Table 5	Proportion of HIV Positive by Gender, Exposure and Year of Diagnosis (Vancouver HSDA)	32
Table 6	Proportion of HIV Positive by Gender, Exposure and Year of Diagnosis (Rest of VCH)	32
Figure 5	Number of Patients' CD4 Cell Count and Disease Stage at Diagnosis by Year of Diagnosis	33
Figure 6	Proportion of Patients' CD4 Cell Count and Disease Stage at Diagnosis by Year of Diagnosis	34
Figure 7	Proportion and Ratio of Patients Diagnosed with CD4 $>$ 500/Acute Stage and CD4 $<$ 200 by Year of Diagnosis	35
Map 4	Mean CD4 Cell Count at Diagnosis by HSDA/LHA – Historical Period	36

Map 5	Mean CD4 Cell Count at Diagnosis by HSDA/LHA – STOP HIV/AIDS Period	36
Section 3 I	Public Health Management Indicators - Graphs, Maps and Tables	37
Figure 8	Proportion of New Diagnoses with Records of Public Health Follow-up	39
Figure 9	Total Number of Contacts Elicited, Contacts per Case and Contacts Notified	40
Figure 10	Proportion of Known Contacts and Average Number of Anonymous Contacts per Index Case	41
Figure 11	Number of Contacts Notified and Tested and Percent Positivity due to Contact Tracing	42
Section 4	Freatment Indicators - Graphs, Maps and Tables	43
Table 7	Proportion of Patients Linked to Care within 30 Days of Diagnosis by Gender, Exposure and Year of Diagnosis (Vancouver HSDA)	47
Table 8	Proportion of Patients Linked to Care within 30 Days of Diagnosis by Gender, Exposure and Year of Diagnosis (Rest of VCH)	47
Table 9	Proportion of Patients Linked to Care within 30 Days of Diagnosis by Gender, Age Group and Year of Diagnosis (Vancouver HSDA)	48
Table 10	Proportion of Patients Linked to Care within 30 Days of Diagnosis by Gender, Age Group and Year of Diagnosis (Rest of VCH)	48
Table 11	Proportion of Patients Currently Retained in Care by Gender, Exposure and Year of Diagnosis (Vancouver HSDA)	49
Table 12	Proportion of Patients Currently Retained in Care by Gender, Exposure and Year of Diagnosis (Rest of VCH)	49
Table 13	Proportion of Patients Currently Prescribed ARVs by Gender, Exposure and Year of Diagnosis (Vancouver HSDA)	50
Table 14	Proportion of Patients Currently Prescribed ARVs by Gender, Exposure and Year of Diagnosis (Rest of VCH)	50
Table 15	Mean Monitored Viral Load, Proportion of HIV Positive Individuals Not Fully Suppressed with Viral Load > 200 Copies/mL (Vancouver HSDA)	51
Table 16	Mean Monitored Viral Load, Proportion of HIV Positive Individuals Not Fully Suppressed with Viral Load > 200 Copies/mL (Rest of VCH)	52
Figure 12	Mean Monitored Viral Load, Proportion of HIV Positive Individuals Not Fully Suppressed	53
Map 6	Mean Monitored Viral Load by Local Health Area – Historical Period	54
Map 7	Mean Monitored Viral Load by Local Health Area – STOP HIV/AIDS Period	54
Appendix A	A Indicator Definitions and Rationale	55
Appendix I	3 Population Monitoring Data Sources	67

Appendix B Population Monitoring Data Sources

Acknowledgements

We would like to acknowledge the contributions of our many partners. Without their support this report would not have been possible.

- BC Centre for Disease Control STI/HIV Control and Lauren MacDonald, Epidemiologist
- BC Centre for Excellence in HIV/AIDS Benita Yip & William Chau, Analysts and Dr. Kate Heath, Epidemiologist
- Microbiology & Virology at Providence Health Care Willson Jang, Technical Leader
- BC Public Health Microbiology and Reference Laboratory
- Vancouver Coastal Health STOP Outreach Team
- Vancouver Coastal Health Communicable Disease Control Margot Smythe, Communicable Disease Nurse Coordinator; Laura Zerr, HIV Communicable Disease Control Nurse & the Communicable Disease Control Nurses
- Vancouver Coastal Health Hope to Health Project Team

Table of Abbreviations

AIDS	Acquired Immune Deficiency Syndrome
ARVs	Antiretroviral therapy (can also be abbreviated as ART)
BC	British Columbia
BCCfE	British Columbia Centre for Excellence in HIV/AIDS
C +/-	An increase or decrease in a particular indicator for current time period compared to previous half-year
CD4	Cluster of differentiation 4, is a marker to identify a type of human T helper cell
DTES	Downtown Eastside, Vancouver
H +/-	An increase or decrease in a particular indicator for current time period compared to the historical time period (January 2008 – June 2010)
HIV	Human Immunodeficiency Virus
HSDA	Health Service Delivery Area
IDU	Injecting Drug Use
LHA	Local Health Area
mL	Milliliter
MSM	Men who have sex with men
POC	Point of Care HIV Test
PHSU	Public Health Surveillance Unit
S +/-	An increase or decrease in a particular indicator for current time period compared to STOP period
STOP	HIV/AIDS Seek and Treat for Optimal Prevention of HIV/AIDS
VCH	Vancouver Coastal Health (Authority)
vL	Viral Load
Y +/-	An increase or decrease, for a particular indicator, in current year-to-date values compared to the previous year-to-date
Q1	Quarter 1 in the calendar year
Q2	Quarter 2 in the calendar year
Q3	Quarter 3 in the calendar year
Q4	Quarter 4 in the calendar year
S 1	The first half of the calendar year
S2	The second half of the calendar year

Cautions/Interpretations

- The data sources used for this report are of a dynamic nature, and subject to change on a frequent basis. The results reported herein are current as of April 11, 2016.
- A number of indicators are susceptible to the longitudinal dynamic nature of the data used for this report, and therefore their values reported for the current time period are expected to change in the next reporting period. For this reason, significant differences should be interpreted with this in mind.
- Through individual-level data linkage this report is able to describe select measures at the population-level for a specific dataset of linked individuals with nearly complete information. Extrapolation of these results to the entire population receiving treatment within VCH, should take this into consideration. For this reason, absolute numbers in particular should be interpreted with caution.
- Since the changes from Quarterly Report to Semi-Annual Report, definitions on several indicators have been changed or modified. Moreover, several indicator numbers also changed to meet the new structure of the Report. Please check the definitions in the Appendix A. The following indicators have definition changes: VCH45a, VCH45b, VCH16, VCH17, VCH17a, VCH19, VCH24, VCH23a, VCH23b, VCH23c, VCH46a, VCH49, VCH52, VCH54.
- In this report, the proportion will not be reported if the denominator is less than 5.

Note: Please always refer to the most recent report.

Section 1. Population Monitoring Report Overview

VCH Semi-Annual Monitoring Report Overview

The VCH STOP Evaluation Task Group approved a complete set of monitoring indicators in April 2011, to be monitored over the course of STOP. In general these indicators report data from across the HIV patient journey, but more specifically they evaluate important components of the core testing, public health management and treatment objectives of the STOP HIV/AIDS pilot project. A rationale and definition of each indicator is provided in Appendix A.

The VCH Monitoring Report presents both a summary table and a series of associated figures, maps and tables.

Summary Table

The summary table reports on the approved monitoring indicators, and is organized by testing, public health management and treatment phase of the patient journey. This table presents data from the current half-year for each indicator, and compares them to data from the preceding three half-year periods, the entire STOP HIV/AIDS pilot project period (July 1, 2010 to current), and to a historical baseline period (January 1, 2008 – June 30, 2010). The table also reports on:

- Counts (or proportions) for the current year to date, and
- Counts (or proportions) for the same time period in the previous year.

Significant differences compared to the preceding half-year (C+/-), the STOP HIV/AIDS period (S+/-), historical baseline period (H+/-), and year-to-date (Y+/-) and are noted in the far right column. Where possible, statistically significant differences (p<0.05) are determined; however, for some indicators significant differences are determined to be values with an increase or decrease of 10%.

Additional Figures, Maps and Tables

Graphs, maps and tables, are prepared to examine the data across different sociodemographic and clinical stratifications. Such graphs are not prepared for every indicator, but rather for a selection with important trends during the current half-year.

Data Sources

The data sources collected and compiled for this report, are described in Appendix B. Individual HIV public health surveillance records were linked using deterministic methods to the BCCfE clinical monitoring and drug treatment program data, creating a unique longitudinal dataset of the HIV continuum within VCH. Of all known HIV diagnoses reported in Vancouver Coastal Health since May 2003, 89% were linked to clinical monitoring and drug treatment records. The remaining 11% are diagnoses who participated in non-nominal testing and are therefore unable to be linked, but may still be engaged in care. Those individuals from the BC CfE database who did not link to HIV surveillance records were primarily (88%) diagnosed before May 2003, the remaining 12% are likely the population of non-nominal testers. Comparative analyses of unlinked individuals to the linked population verify that the linked dataset is representative of the

greater population of all known HIV positive individuals across VCH on a number of sociodemographic, clinical and epidemiological characteristics. For more detailed information please refer to the Q1 2012 report (http://www.vch.ca/media/Q1 20_012-Monitoring-Report_STOP-HIV-AIDS.pdf).

Summary Table Results S2 (July 1 – December 31, 2015)

Testing Indicators

- The number of POC tests from POC test sites engaged in STOP HIV/AIDS initiatives decreased significantly compared to the average since STOP, and year to date. The number of new positives from POC tests decreased compared to the average since STOP and year to date [VCH1, VCH4a].
- Overall HIV lab testing volumes from VCH <u>residents</u>, <u>or those who tested in VCH</u>, slightly declined compared to the first half of 2015 although the current volume is significantly higher than the average since STOP, historical and year to date. In S2 2015, volumes increased 46% compared to the average since STOP, and were 165% higher than the historical baseline [VCH8a].
- HIV lab test volumes from <u>clinics</u> in VCH slightly declined compared to the first half of 2015 although the current volume is significantly higher than the average since STOP and in comparison to the historical baseline and year to date [VCH8b]. Compared to the average since STOP, Richmond HSDA had the highest increase (84%), followed by Coastal Urban (82%), Coastal Rural (65%) and Vancouver (37%).
- HIV lab tests among residents of VCH remained steady compared to the first half of 2015 and significantly increased in comparison to the average since STOP, the historical baseline and year-to-date [VCH11a]. Compared to the average since STOP, Richmond HSDA had the highest increase (76%), followed by Coastal Urban (71%), Coastal Rural (59%) and Vancouver (40%).
- HIV lab tests from non-VCH residents who tested in VCH [VCH11d] decreased slightly compared to the first half of 2015 although remains significantly higher than the average since STOP, the historical baseline, and year-to-date.
- The number of newly reported HIV positives from VCH significantly decreased in comparison to the preceding periods, the average since STOP, and historical [VCH13a]. Eighty-seven percent of cases were reported among Vancouver residents.
- The percent positivity of HIV testing [VCH14a] significantly decreased in VCH and Vancouver HSDA compared to the average since STOP and the historical baseline. The decline in percent positivity since STOP may be attributed to the broader testing strategy that is generating a greater number of HIV tests in lower risk settings as well as the sustained increase in overall testing volumes. Due to a small number of positives in Richmond, Coastal Urban and Coastal Rural, the percent positivity is likely to fluctuate.
- In this reporting period, the proportion of new HIV positive cases diagnosed with a CD4 count >= 500 cells/mm³ or with acute stage disease [VCH45a] is the highest observed since HIV became reportable 2003 with 59% of new diagnoses being diagnosed early. In Vancouver HSDA, 64% of new diagnoses were diagnosed with early stage disease which is significantly higher than historical and is the highest ever observed.
- The proportion of new HIV positive cases diagnosed with a CD4 count < 200 cells/mm³ [VCH45b] is lower than the average since STOP and the historical baseline. The proportion of cases reported in the rest of VCH (except Vancouver), with a CD4 count <200 cell/mm³ should be interpreted with caution due to small case numbers.

Public Health Management Indicators

These indicators were established to measure public health management activities augmented for STOP HIV/AIDS. Data are collected by public health practitioners using a partner notification form developed for this purpose. As a result, baseline data prior to STOP HIV/AIDS are not available.

- The proportion of new positives with a record of public health follow-up decreased in comparison to the preceding periods [VCH16] and the average since STOP. It is important to note that the public health management indicators are based on the case diagnosis date and therefore are likely to change as follow-up is completed over time.
- The number of partners elicited decreased significantly compared to the preceding periods, the average since STOP, and year to date [VCH17].
- The average number of partners elicited per positive case is similar to the preceding periods, the average since STOP and year-to-date [VCH17a]. An average of 3 partners per case was elicited in the most recent period.
- The proportion of partners notified increased significantly compared to the preceding periods. However, the proportion of partners notified year to date is the same as in 2014 [VCH19].
- The proportion of notified partners that were known to be previously HIV positive decreased compared to the preceding periods and the average since although not significantly [VCH24].
- The proportion of notified partners known to be tested for HIV is the highest proportion observed since the program started at 81%. It is significantly higher than the preceding period and the average since STOP [VCH23a].
- Six new HIV positive cases were diagnosed through public health follow-up during the most recent period, which is significantly higher than the average since STOP and year to date [VCH23b].
- The percent positivity in the second half of 2015 was 11%, which is higher than the average since STOP although not significantly [VCH23c].

Treatment Indicators

- The proportion of new diagnoses linked to care within 30 days in Vancouver HSDA is lower than the average since STOP, although is higher than the historical baseline [VCH41]. Among the rest of VCH residents in this period, the proportion linked to care within 30 days was higher than average since STOP and the historical baseline. This should be interpreted with caution due to a small number of new positives in Richmond, Coastal Urban and Coastal Rural.
- The median time to linkage to HIV care in VCH was 6 days and remains below the average in the historical baseline [VCH44b].
- The proportion of HIV patients currently retained in care remained stable compared to the preceding periods, the average since STOP, historically and year-to-date [VCH46]. 90% of Richmond residents were currently retained in care, followed by Coastal Rural (84%), Vancouver (79%) and Coastal Urban (78%).
- The proportion of patients not found in care did not change significantly when compared to the preceding periods, the average since STOP, the historical baseline and year-to-date [VCH47b]. The proportion of patients not found in care in Coastal Urban decreased slightly when compared to the preceding periods. In the most recent period, 22% of

Coastal Urban residents were not found in care, followed by Vancouver (19%), Richmond (13%) and Coastal Rural (12%).

- The proportion of patients currently prescribed ARVs significantly increased compared to the average since STOP and the historical baseline [VCH48]. Conversely, the proportion of patients who discontinued and did not restart ARVs decreased significantly compared to the average since STOP and the historical baseline [VCH49].
- The proportion of individuals newly taking ARVs and achieving viral suppression (viral load < 200 copies/mL) within 9 months of treatment within Vancouver HSDA is similar to the average since STOP [VCH51]. *It is important to note that this indicator is influenced by a lag in data capture.*
- The proportion of individuals on ARVs achieving viral suppression with viral load <200 copies/mL increased significantly compared to the historical baseline [VCH52]. The greatest proportion of individuals achieving viral suppression was observed in Coastal Urban HSDA with 98% followed by Coastal Rural with 94%.
- The mean monitored viral load of all known HIV positive individuals in VCH continues to decline and was significantly lower than the average since STOP, the historical baseline, and year to date [VCH53].
- The proportion of individuals with a viral load >200 copies/ml (not suppressed) is the lowest observed with 14% and is significantly lower than the average since STOP and the historical baseline [VCH54].



STOP HIV/AIDS Monitoring Indicators Semi-Annual Summary Report S2 (July 1 – December 31, 2015)



How you want to be treated.

Indicat	or Number	Indicator Name		Counts by	y Half-Year			OP HIV/AI 1, 2010 to			orical Base 008 to Jun		Year to Date Cases		Significance
			Jul-Dec 2015	Jan-Jun 2015	Jul-Dec 2014	Jan-Jun 2014	Avg	Min	Max	Avg	Min	Max	Year 2015	Year 2014	
	VCH1	Number of POC tests	3114	3260	3724	3728	3872	792	8669	N/A	N/A	N/A	6374	7452	S-Y-
	VCH4a	Number of new true positive POC tests	4	16	14	22	19	3	41	N/A	N/A	N/A	20	36	C-S-Y-
	VCH8a	Overall number of HIV lab tests (either from VCH residents or those who tested at a VCH clinic)	101725	102153	94480	85956	69868	39382	102153	38382	37552	39559	203878	180436	S+H+Y+
	VCH8b	Number of HIV lab tests from all clinics in VCH	97772	98689	91422	83570	67452	37475	98689	36410	35560	37579	196461	174992	S+H+Y+
	VCH8b.1	Vancouver	74137	75106	69506	66337	54261	30356	75106	29444	28683	30531	149243	135843	S+H+
	VCH8b.2	Richmond	10235	10807	10594	8599	5569	2350	10807	2330	2228	2421	21042	19193	S+H+
	VCH8b.3	Coastal Urban	8977	8605	7127	5467	4936	3053	8977	2975	2898	3104	17582	12594	S+H+Y+
	VCH8b.4	Coastal Rural	4423	4171	4195	3167	2686	1634	4423	1661	1619	1731	8594	7362	S+H+Y+
	VCH11a*	Number of HIV lab tests from residents of VCH	87224	87086	81096	73428	58791	31986	87224	30991	30205	31982	174310	154524	S+H+Y+
	VCH11a.1*	Vancouver	60723	60225	56109	53191	43274	23650	60723	23039	22339	23828	120948	109300	S+H+Y+
	VCH11a.2*	Richmond	11869	12665	12292	10146	6734	2960	12665	2814	2673	2917	24534	22438	S+H+
	VCH11a.3*	Coastal Urban	9655	9247	7809	6354	5653	3441	9655	3326	3249	3407	18902	14163	S+H+Y+
	VCH11a.4*	Coastal Rural	4977	4949	4886	3737	3129	1845	4977	1812	1767	1862	9926	8623	S+H+Y+
S	VCH11d	Number of HIV lab tests from known non- residents of VCH, who tested in VCH	14501	15067	13384	12528	11078	7396	15067	7390	7292	7641	29568	25912	S+H+Y+
Testing Indicators	VCH13a*	Number of positive HIV diagnoses for VCH residents	60	76	60	86	75	60	98	87	77	100	136	146	C-S-H-
sting Ir	VCH13a.1*	Vancouver	52	67	52	80	68	52	87	80	72	94	119	132	C-S-H-
Te	VCH13a.2*	Richmond	-	7	-	-	-	-	7	-	-	5	9	-	C-S-H-Y+
	VCH13a.3*	Coastal Urban	5	-	-	-	-	-	5	-	-	-	6	5	C+S+H+Y+
	VCH13a.4*	Coastal Rural	-	-	-	-	-	-	-	-	-	-	-	5	S-H+Y-
	VCH14a	Percent positivity (%) of VCH residents	0.07	0.09	0.07	0.12	0.13	0.07	0.28	0.28	0.25	0.33	0.08	0.09	S-H-
	VCH14a.1	Vancouver	0.09	0.11	0.09	0.15	0.16	0.09	0.32	0.35	0.32	0.42	0.10	0.12	S-H-
	VCH14a.2	Richmond	-	0.06	-	-	-	-	0.17	-	-	0.17	0.04	-	
	VCH14a.3	Coastal Urban	0.05	-	-	-	-	-	0.11	-	-	-	0.03	0.04	
	VCH14a.4	Coastal Rural	-	-	-	-	-	-	-	-	-	-	-	0.06	
	VCH45a	Proportion of all VCH HIV patients with CD4 count > 500 cells/mm3 or acute stage at diagnosis (%)	59	42	42	53	47	40	59	41	35	53	49	49	
	VCH45a.1	Vancouver	64	47	48	56	50	42	64	42	34	56	54	53	H+
	VCH45a.2		40	50	17	25	31	0	50	25	0	67	43	20	
	VCH45b	Proportion of all VCH HIV patients with CD4 count < 200 cells/mm3 at diagnosis (%)	13	17	18	13	19	12	25	22	16	33	16	15	
	VCH45b.1	Vancouver	8	15	17	10	17	8	26	21	14	30	12	12	
	VCH45b.2	Rest of VCH	40	0	33	25	27	0	50	44	0	100	29	30	

Notes

• *This includes testers or positives who have known residential information within VCH and those who test in VCH but do not have available residential information.

• Data used for this report are longitudinal and of dynamic nature, with many indicators being subject to a lag in time to reporting. Therefore indicator values are likely to change with continual data updating.



Interpretation

- C +/- represents an increase or decrease for current time period compared to preceding period
- S +/- represents an increase or decrease for current time period compared to STOP Period (July 1, 2010 to current)
- H+/- represents an increase or decrease for current time period compared to historical time period (January 2008-June 2010)
- Y +/- represents an increase or decrease for current year-to-date compared to previous year-to-date
- "-"represents a suppressed cell where the value is derived from a number of individuals less than 5 in a defined region.
- STOP HIV/AIDS average is the average of all half-years since July 1, 2010, with the minimum and maximum during all half-years since STOP. This also applies to historical baseline average.



STOP HIV/AIDS Monitoring Indicators Semi-Annual Summary Report S2 (July 1 – December 31, 2015)



Indicat	or Number	Indicator Name	Counts by Half-Year				STOP HIV/AIDS (July 1, 2010 to date)				torical Bas 2008 to Jui	seline n 30, 2010)	Year to Date Cases		Significance
			Jul-Dec 2015	Jan-Jun 2015	Jul-Dec 2014	Jan-Jun 2014	Avg	Min	Max	Avg	Min	Мах	Year 2015	Year 2014	
	VCH 16	Proportion of new positives with record of public health follow-up	83	96	93	95	94	83	100	N/A	N/A	N/A	90	95	
Public Health Management Indicators	VCH17	Number of partners elicited	149	247	157	312	263	149	395	N/A	N/A	N/A	396	469	C-S-Y-
		Average number of partners elicited per positive case	3	3	3	4	4	3	5	N/A	N/A	N/A	3	3	
	VCH19	Proportion of partners notified (%)	52	39	38	48	45	34	57	N/A	N/A	N/A	44	44	C+
th Man	VCH24	Proportion of notified partners who were known to be previously HIV positive (%)	13	23	15	19	18	11	23	N/A	N/A	N/A	18	18	
Public Healt		Proportion of notified partners tested for HIV (%)	81	57	60	76	60	48	81	N/A	N/A	N/A	69	71	C+S+
	VCH23b	Number of notified partners who tested HIV positive	6	6	4	3	5	1	7	N/A	N/A	N/A	12	7	S+Y+
		Percent positivity (%) due to Partner Notification	11	14	13	3	8	2	14	N/A	N/A	N/A	12	6	

Notes

• Data used for this report is longitudinal and of a dynamic nature, with many indicators being subject to a lag in time to reporting. Therefore indicator values are likely to change with continual data updating.



Interpretation

• \hat{C} +/- represents an increase or decrease for current time period compared to preceding period

• S +/- represents an increase or decrease for current time period compared to STOP Period (July 1, 2010 to current)

• H +/- represents an increase or decrease for current time period compared to historical time period (January 2008-June 2010)

• Y +/- represents an increase or decrease for current year-to-date compared to previous year-to-date

• STOP HIV/AIDS average is the average of all half-years since July 1, 2010, with the minimum and maximum during all half-years since STOP. This also applies to historical baseline average.



STOP HIV/AIDS Monitoring Indicators Semi-Annual Summary Report S2 (July 1 – December 31, 2015)



Number Addres Addres<	Indica	tor Number	Indicator Name		Counts by	Half-Year			OP HIV/AI 1, 2010 to			torical Base 008 to Jun		Year to Date Cases		Significance
Vertify Index or areal m3 3 days of m2 77 80 96 64 54 71 70 77 64 96 97 77 64 97 77 64 97 70 80 78 70 80 78 70 80 78 70 80 70 70 80 80 70 70 80 80 70 80 70 70 80 70	Indica	tor Number	Indicator Name					Avg	Min	Max	Avg	Min	Max			Significance
VCH11 VCH12 VCH141 VCH141 <td></td> <td>VCH41</td> <td>linked to care within 30 days of</td> <td>75</td> <td>80</td> <td>70</td> <td>79</td> <td>77</td> <td>68</td> <td>86</td> <td>64</td> <td>54</td> <td>71</td> <td>78</td> <td>75</td> <td></td>		VCH41	linked to care within 30 days of	75	80	70	79	77	68	86	64	54	71	78	75	
VD44 The b index b M varm minu 6 7 6 10 11 9 13 6 7 6 9 VCH40 Worksing drag with W with W 70 80 81 81 81 81 81 81 81 70 77 78 81 81 81 81 81 81 81 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td>-</td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>								-								
VCH40: VCH40:<			Time to linkage to HIV care among those newly diagnosed with HIV within													C-S-H-
VCH4B Proportion of HV palemit Mo are view in VCH in view in vin view in VCH in view in view in VCH in view in view			Vancouver													C-S-H-Y-
VCH464 VCH464<			Proportion of HIV patients who are currently retained in care within VCH					-								H
VCH406.3 COunsel Links 78 80 78 <td></td> <td></td> <td>Vancouver</td> <td></td>			Vancouver													
VCH4024 CCM4024 CCM4025 COM4025 COM4025 <t< td=""><td></td><td></td><td></td><td></td><td></td><td>•••</td><td></td><td></td><td>•••</td><td></td><td></td><td></td><td></td><td></td><td>•••</td><td></td></t<>						•••			•••						•••	
VEHTE Proposition of matched HV patients into load in care within VCH (%). 19 18 18 18 18 20 19 18 VCHATD: VCHATD: Care within VCH (%). 13 14 18 18 16 19 18 3 9 13 13 13 VCHATD: Care within VCH (%). 70 23 25 6 0 7 0 13 22 25 27 28 22 13 28 16 9 21 22 27 70 13 20 5 35 12 6 0 70 66 67 58 70 64 54 75 85 55 35 12 68 84 64 63 64 59 70 68 84 84 74 84 74 84 74 83 76 84 84 74 73 73 26 75 85 12 13																
VCHU2 Observed Participant Observed Participant Page Participant Page Page Participant Page Page Participant Page Page Participant Page Page Page Page Page Page Page Page		VCH46a.4		84	81	81	84	81	65	93	66	53	78	84	81	
VCHVD-2 Constal Uban 12 14 13 10 11 7 14 6 3 9 13 13 13 VCHVD-2 Constal Uban 12 25 6 0 7 0 13 25 27 28 27 13 12 16 9 21 22 27 VCHW3 Constal Wan ex currently Pescribed ARVs with VCH (%) 70 69 69 69 65 57 69 47 40 54 69 69 69 70			found in care within VCH (%)													
VCH470-3 Coastal Luban 22 25 27 28 22 13 28 16 9 21 22 27 28 VCH470-3 Coastal Lural 12 5 6 0 7 0 13 20 5 355 12 6 VCH48 Proportion of patents who are currently 70 60 60 60 67 60 47 60 48 64 63 64 <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td><td></td></t<>																
VCH476.4 Coastal Rura 12 5 6 0 7 0 13 20 55 35 12 6 VCH48.1 Proportion of patients with VCH (%) 70 60 69 69 67 58 70 68 44 65 70 69 48 41 55 60 65 57 69 65 53 53 57 69 65 53 53 53 69 66 57 69 65 53 53 69 68 69 68 69 68 69 61 52 68 69 64 68 69 61 52 68 69 64 68 69 61 52 68 69 61 52 68 69 61 52 68 69 61 52 63 53 53 53 53 53 53 53 53 53 53 64							-									
VCH48 Proportion of patients who are currently presentined ARXs within VCH (%) Production of all volume Production volume Production volume Production of all volume Production volume																
VCH8 Prescribed ARVs within VCH (%) N0 R9 69 69 60 69 60 69 60 69 47 40 54 69 69 64 VCH83 Varcouver 69 69 69 66 57 69 47 40 54 69 69 64 VCH843 Coastal Urban 69 70 64 63 64 59 70 55 53 57 69 64 64 64 64 68 69 61 52 68 89 64 64 64 66 68 61 52 50 12 13 13 13 16 12 27 39 31 49 12 13 13 13 16 12 22 52 21 30 11 19 2 14 14 14 14 14 14 14 14 14 14 14							-	-	-			-			-	
VCH48.2 Charmad 81 78 82 85 79 67 85 66 48 76 81 62 VCH48.3 Coassal Uhan 69 70 64 63 64 69 70 55 53 53 67 69 64 64 VCH49 Coassal Uhan 69 70 64 <td></td> <td></td> <td>prescribed ARVs within VCH (%)</td> <td></td> <td>S+H+</td>			prescribed ARVs within VCH (%)													S+H+
VCH48.3 Coastal l/ban 69 70 64 63 64 59 70 55 53 57 69 64 64 VCH48.4 VCH48.4 Proportion of patients with Nucle (%) 12 12 13 13 16 12 27 39 31 49 12 13 51 VCH49.1 VCH49.2 VCH49.1 VCH49.1 VCH49.2 VCH49.1 VCH49.2 VCH49.3 Coastal l/ban 11 12 19 21 18 11 22 25 21 30 13 5 12 6 10 5 25 12 10 7 13 7 28 27 14 46 7 10 14 10 12 19 21 18 11 22 25 23 35 5 12 14 10 10 10 10 10 10 10 10 10 10 10 10																H+
VCH48.4 VCH49 Coastal Rural Continued and currently within the resistante discontinued and currently within the resistant discontinued and discontinued and within VCH new discontinued and within VCH appressed with within a months are within VCH and as than 200 copies/mL within VCH and as than 200 copies/mL within VCH and sets than 200 copies/mL within VCH and sets than 200 copies/mL within VCH and sets than 200 copies/mL within VCH (%). 97 95 93 92 88 97 90 87 91 93 95 VCH51.1 Proportion of all individuals within VCH new disting ARVs who are urrently within a months are with with and bets than 200 copies/mL with vCH and sets than 200 copies/mL with vCH (%). 86 86 86 86 86 86 86 87 78 74 81 85 66 VCH52.1 VCH52.1 VCH53.1 VCH53.1 VCH																
Proportion of individuals within VCH Proportion of individuals within VCH Point Proportion of all individuals on ARVs Point Proportion of all individuals with Proportion of all individuals on ARVs Point Proportion of all individuals with Proportion of all individuals on ARVs Point Proportion of all individuals with Proportion of all individuals Proportion of all																
Proportion of individuals within VCH Proportion of individuals within VCH Point Proportion of all individuals on ARVs Point Proportion of all individuals with Proportion of all individuals on ARVs Point Proportion of all individuals with Proportion of all individuals on ARVs Point Proportion of all individuals with Proportion of all individuals Proportion of all	ors	VCH48.4		89	87	84	84	83	68	89	61	52	68	89	84	H+
Proportion of individuals within VCH Proportion of individuals within VCH Point Proportion of all individuals on ARVs Point Proportion of all individuals with Proportion of all individuals on ARVs Point Proportion of all individuals with Proportion of all individuals on ARVs Point Proportion of all individuals with Proportion of all individuals Proportion of all	Indicat	VCH49	discontinued and currently not restarted	12	12	13	13	16	12	27	39	31	49	12	13	S-H-
VCH51 Proportion of individuals within VCH 0 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0 0 0 1 0	ť	VCH49.1	Vancouver	12	13	13	13	16	12	28	40	32	50	12	13	S-H-
Proportion of individuals within VCH Proportion of individuals within VCH Point Proportion of all individuals on ARVs Point Proportion of all individuals with Proportion of all individuals on ARVs Point Proportion of all individuals with Proportion of all individuals on ARVs Point Proportion of all individuals with Proportion of all individuals Proportion of all	a n	VCH49.2	Richmond	7	12	10	7	13	7	28	27	18	46	7	10	H
Proportion of individuals within VCH Proportion of individuals within VCH Point Proportion of all individuals on ARVs Point Proportion of all individuals with Proportion of all individuals on ARVs Point Proportion of all individuals with Proportion of all individuals on ARVs Point Proportion of all individuals with Proportion of all individuals Proportion of all	eat	VCH49.3	Coastal Urban	11	12	19	21	18	11	22	25	21	30	11	19	
VCH61 newly taking ARVs who are virally suppressed with viral load less than 200 copiesrim. within a monthe since treatment start (%) 92 97 95 93 92 88 97 90 89 91 92 95 VCH51.1 Vancouver 93 97 95 93 92 88 97 90 87 91 93 95 VCH51.2 Vancouver 85 100 93 94 96 87 100 93 85 100 87 93 85 100 87 93 85 100 87 93 85 100 87 93 85 100 87 93 85 100 87 93 85 100 87 93 85 100 93 84 80 87 81 85 86 86 84 79 86 78 74 81 85 86 86 84 79 86 72 93 98 89<	Ĕ	VCH49.4	Coastal Rural	5	5	12	6	10	5	25	29	23	35	5	12	H
VCH51.2 Rest of VCH 87 100 93 96 87 100 93 85 100 87 93 VCH52 Proportion of all individuals on ARVs within VCH (%) na nas <		VCH51	newly taking ARVs who are virally suppressed with viral load less than 200 copies/mL within 9 months since	92	97	95	93	92	88	97	90	89	91	92	95	
Proportion of all individuals on ARVs who are currently virally suppressed with viral load less han 200 copies/nL within VCH (%) 86 86 87 87 84 80 87 78 74 81 86 87 84 VCH52.1 VCH52.2 Wanne 200 copies/nL within VCH (%) 85 85 86 86 84 79 86 78 74 81 85 86 86 84 79 86 78 74 81 85 86 86 84 79 86 78 74 81 85 86 86 84 79 86 78 74 81 85 86 86 84 79 86 78 74 81 89 90 95 90 95 90 95 90 95 90 93 91 93 89 84 67 94 85 69 100 94 93 90 95 100 94 93 96 65		VCH51.1	Vancouver	93	97	95	93	92	88	97	90	87	91	93	95	
VCHS2 with viral load less than 200 copies/mL with vCH (%) 86 66 87 87 84 80 87 78 74 81 80 87 PH VCH52.1 Vancouver 85 85 86 86 84 79 86 78 74 81 85 86 H+ VCH52.2 Richmond 90 94 95 89 87 69 96 80 71 89 90 95 95 VCH52.3 Coastal Urban 98 96 89 93 91 84 98 86 72 93 98 89 14 98 86 72 93 98 89 14 98 86 72 93 98 89 86 73 86 73 98 89 85 69 100 94 93 98 84 67 94 85 69 100 94 93 98		VCH51.2	Proportion of all individuals on ARVs	87	100	93	94	96	87	100	93	85	100	87	93	
VCH52.2 Richmond 90 94 95 89 87 69 96 80 71 89 90 95 N VCH52.3 Coastal Urban 98 96 89 93 91 84 98 86 72 93 98 89 91 93 89 84 67 94 85 69 100 94 93 96 89 84 67 94 85 69 100 94 93 96 88 54 188 393 225 779 57 66 C-S-F VCH53.4 VCH53.2 Vancouver 55 62 62 70 90 55 193 417 235 819 59 65 C-S-F VCH53.4 VCH53.3 Coastal Urban 54 39 68 72 72 39 157 178 102 555 53 67 C+S-F VCH53.4			with viral load less than 200 copies/mL within VCH (%)													
VCH52.3 Coastal Urban 98 96 89 93 91 84 98 86 72 93 98 89 H+ VCH52.4 Coastal Rural 94 91 93 89 84 67 94 85 69 100 94 93 94 94 93 94 93 89 84 67 94 85 69 100 94 93 94 94 94 94 94 94 93 94 89 84 67 94 85 69 100 94 93 94 94 93 94 94 94 93 94								-								H+
VCH52.4 Coastal Rural 94 91 93 89 84 67 94 85 69 100 94 93 VCH53 Mean monitored Viral load (copies/mL) of all known HIV positive individuals 54 61 61 69 88 54 188 393 225 779 57 64 C-S-H VCH53.1 Vancouver 55 62 62 70 90 55 193 417 235 819 59 65 C-S-H VCH53.2 Richmond 42 60 36 53 66 36 179 266 112 635 42 41 C-S-H VCH53.3 Coastal Wran 41 41 85 44 41 183 170 89 437 41 63 54 54 54 54 54 54 54 54 54 54 54 54 44 44 183 170 89 437																
Mean monitored viral load (copies/mL) of all known HIV positive individuals within VCH 54 61 61 69 88 54 188 393 225 779 57 64 C-S-H VCH53.1 VCH53.1 Vancouver 55 62 62 70 90 55 193 417 235 819 59 65 C-S-H VCH53.2 Richmond 42 60 36 53 66 36 179 266 112 635 42 41 C-S-H VCH53.3 Coastal Urban 54 39 68 72 72 39 157 178 102 555 53 67 C-S-H VCH53.4 Coastal Urban 54 39 68 72 72 39 157 178 102 555 53 67 C-S-H VCH53.4 Coastal Rural 41 41 85 44 84 41 183 170 89 437																H+
VCH53. of all known HIV positive individuals 54 61 61 69 88 54 188 393 225 779 57 64 C-S-H C-S-H C-S-H VCH53.1 VCH53.2 VCH53.2 VCH53.2 VCH53.3 VCH53.3 Coastal Urban 54 60 36 53 66 36 179 266 112 635 42 41 C-S-H VCH53.2 Richmond 42 60 36 53 66 36 179 266 112 635 42 41 C-S-H VCH53.3 Coastal Urban 54 39 68 72 72 39 157 178 102 555 53 67 C-S-H VCH53.4 Coastal Wrbin 41 41 85 44 41 183 170 89 437 41 80 S-H VCH54.4 Proportion of all individuals with viral VCH (%) 14 15 15 18 21		VCH52.4		94	91	93	89	84	67	94	85	69	100	94	93	
VCH53.2 Richmond 42 60 36 53 66 36 179 266 112 635 42 41 C-S- VCH53.3 Coastal Urban 54 39 68 72 72 39 157 178 102 555 53 67 C+S- VCH53.4 Coastal Urban 41 41 85 44 84 41 183 170 89 437 41 80 S+H VCH54.4 Proportion of all individuals with virtin VCH(%) 14 15 15 18 21 14 36 47 39 58 21 23 S+H VCH54.1 Vancouver 14 15 15 18 22 14 37 48 40 59 22 24 S+H VCH54.2 Richmond 12 12 5 13 16 5 37 42 29 50 17 16 H <td></td> <td>VCH53</td> <td>of all known HIV positive individuals</td> <td>54</td> <td>61</td> <td>61</td> <td>69</td> <td>88</td> <td>54</td> <td>188</td> <td>393</td> <td>225</td> <td>779</td> <td>57</td> <td>64</td> <td>C-S-H-Y-</td>		VCH53	of all known HIV positive individuals	54	61	61	69	88	54	188	393	225	779	57	64	C-S-H-Y-
VCH53.3 Coastal Urban 54 39 68 72 72 39 157 178 102 555 53 67 C+S+ VCH53.4 Coastal Rural 41 41 85 44 84 41 183 170 89 437 41 80 S+H VCH54 Proportion of all individuals with viral load greater than 200 copy/mL within VCH(%) 14 15 15 18 21 14 36 47 39 58 21 23 S-H VCH54.1 VCH54.2 VCH54.2 VCH54.2 VCH54.2 VCH54.2 VCH54.2 VCH54.1 VCH54.2 VCH54.1 VCH54.2				55	62	62	70	90	55	193	417	235	819	59	65	C-S-H-
VCH53.4 Coastal Rural Proportion of all individuals with viral load greater than 200 copy/mL within VCH54.1 41 41 85 44 84 41 183 170 89 437 41 80 S-H- VCH54 Proportion of all individuals with viral VCH(%) 14 15 15 18 21 14 36 47 39 58 21 23 S-H VCH54.1 VCH54.2 Vancouver 14 15 15 18 22 14 37 48 40 59 22 24 S-H VCH54.2 Richmond 12 12 5 13 16 5 37 42 29 50 17 16 H	1						•••									C-S-H-
VCH54 Proportion of all individuals with viral load greater than 200 copy/mL within VCH (%) 14 15 15 18 21 14 36 47 39 58 21 23 S-H VCH54.1 VCH54.2 Vancouver 14 15 15 18 22 14 37 48 40 59 22 24 S-H VCH54.1 VCH54.2 Richmond 12 12 5 13 16 5 37 42 29 50 17 16 H	1	VCH53.3	Coastal Urban	54	39	68	72	72	39	157	178	102	555	53	67	C+S-H-Y-
VCH54 load greater than 200 copy/mL within VCH (%) 14 15 15 18 21 14 36 47 39 58 21 23 S-H VCH (%) VCH (%) VCH (%) Vancouver 14 15 15 18 22 14 37 48 40 59 22 24 S-H VCH54.1 VCH54.2 Richmond 12 12 5 13 16 5 37 42 29 50 17 16 H-H	1	VCH53.4		41	41	85	44	84	41	183	170	89	437	41	80	S-H-Y-
VCH54.1 Vancouver 14 15 15 18 22 14 37 48 40 59 22 24 S-H VCH54.2 Richmond 12 12 5 13 16 5 37 42 29 50 17 16 H		VCH54	load greater than 200 copy/mL within	14	15	15	18	21	14	36	47	39	58	21	23	S-H-
		VCH54.1		14	15	15	18	22	14	37	48	40	59	22	24	S-H-
	1	VCH54.2	Richmond	12	12	5	13	16	5	37	42	29	50	17	16	H
VCH54.3 Coastal Urban 11 6 16 13 17 6 31 32 22 55 14 17 H-		VCH54.3	Coastal Urban	11	6	16	13	17	6	31	32	22	55	14	17	H-
VCH54.4 Coastal Rural 8 5 19 13 21 5 38 40 33 53 10 25 H-	1	VCH54.4	Coastal Rural	8	5	19	13	21	5	38	40	33	53	10	25	H-



Notes

- The analyses for most of treatment indicators are based on the individuals in a linked dataset of PHSU HIV Surveillance data and BCCfE Drug Treatment Program data. Except for indicators VCH41 and VCH44b, which use the full PHSU HIV Surveillance dataset and BCCfE Drug Treatment Program Data.
- Data used for this report is longitudinal and of a dynamic nature, with many indicators being subject to a lag in time to reporting. Therefore indicator values are likely to change with continual data updating.
- Treatment indicator denominators are described in appendix A and change overtime as new diagnoses are added and indicator restrictions adjust case population. For an example of case volume; denominators for S2 2013 VCH48 were as follows: Vancouver (n=1,909), Richmond (n=63), Coastal Urban (n=71), Coastal Rural (n=39).

Interpretation

- C +/- represents an increase or decrease for current time period compared to preceding period
- S+/- represents an increase or decrease for current time period compared to STOP Period (July 1, 2010 to current)
- H+/- represents an increase or decrease for current time period compared to historical time period (2008-2009)
- Y +/- represents an increase or decrease for current year-to-date compared to previous year-to-date
- STOP HIV/AIDS average is the average of all half-years since July 1, 2010, with the minimum and maximum during all half-years since STOP. This also applies to historical baseline average.

Section 2. Testing Indicators

Figures, Maps and Tables

Figure 1. Number and Percent Positivity of HIV POC Tests

The number of POC tests decreased significantly in the second half of 2015 compared to the average since STOP and year to date. Additionally, the percent positivity decreased significantly compared to the preceding periods, the average since STOP and year to date.

Table 1. Number of HIV Lab Tests by HSDA/LHA of Testing Clinic

HIV Lab tests in Vancouver and Richmond HSDAs declined compared to the previous half year. Vancouver LHAs including City Centre, Westside, South and Midtown experienced marginal decreases in testing numbers while volumes increased in Vancouver DTES and Vancouver Northeast was observed. HIV test volumes in North Vancouver had the greatest increase with 44% year to date in 2015 compared to 2014, followed by Howe Sound (38%).

Maps 1-3. Mean Monthly HIV Lab Tests per 10,000 population among VCH residents

Since the expansion, average monthly HIV testing rates remained high compared to the STOP pilot period and historical. Compared to the average rate in the STOP Pilot period, most noticeable increases were observed in Powell River (279%), followed by Richmond (105%) and Howe Sound (92%).

Figure 2. Number and Percent Positivity of HIV Lab Tests among VCH Residents

The number of HIV lab tests among residents of VCH increased steadily from the initiation of STOP HIV/AIDS. However, in S2 2015 the HIV testing volume remained similar to the previous half year. As HIV lab tests increased since 2011, there has been a declining trend in percent positivity.

Figure 3. Number and Percent Positivity of HIV Lab Tests among VCH Residents by HSDA

The trend in HIV lab testing in Vancouver HSDA was similar to VCH overall as the majority of tests were conducted among Vancouver residents.

Testing volumes increased substantially in Richmond since 2014 while a gradual increase was observed in Coastal Urban since 2014 and a slight increase was observed in Coastal Rural among known residents of each HSDA. Due to the small number of identified positives, the percent positivity fluctuates by year in Richmond, Coastal Urban and Coastal Rural.

Table 2. Monthly Average of HIV Lab Tests, Population Rate of HIV Lab Tests, HIV Positives and Percent Positivity among VCH residents by HSDA/LHA

Significant increases in the monthly average and rate of HIV lab tests were seen across all HSDAs/LHAs since April 2013. HIV tests increased by 346% in Powell River compared to the historical baseline, followed by Howe Sound (177%), and Richmond (146%).

No significant differences were observed in the monthly average of new HIV positives compared to the STOP pilot or historical. However, the percent positivity has declined across time periods in Richmond, Coastal Urban, and Vancouver HSDAs.

Table 3, 4. Percent Positivity of HIV Lab Tests among VCH Residents by Gender and Age Group

Vancouver HSDA (Table 3)

The percent positivity for HIV testing is highest among males aged 20-29 in S2 2015 followed by males aged 50-59 years. The percent positivity in this age group decreased from 0.67% in S1 2015 to 0.44% in S2 2015. Among males aged 50-59 years, percent positivity decreased compared to the preceding half-year as well from 0.40% in S1 2015 to 0.29% in S2 2015. In comparison with historical baseline, the percent positivity decreased among all males.

While the percent positivity among female age groups are lower overall compared with males, the highest percent positivity was observed among those aged 30-39 and 40-49 in the second half of 2015. Percent positivity among females of all age groups decreased compared to the historical average.

Rest of VCH (Table 4)

The percent positivity across age groups among males continues to fluctuate each period due to low volumes of new diagnoses. The overall percent positivity for this most recent period among men is below the average since STOP HIV/AIDS and the historical baseline. The age group with the highest percent positivity in this period was among men aged 30-39.

The percent positivity across age groups among females continues to fluctuate each period due to low volumes of new diagnoses.

Figure 4. Proportion of New HIV Positives by Gender and Males/Females Ratio by Year of Diagnosis

Vancouver HSDA:

More males were diagnosed compared to females in 2015 (7 males to 1 female). However, 2015 had the highest proportion of new diagnoses being female (13%) since 2010. The majority of new diagnoses (87%) in Vancouver continue to be among males.

Rest of VCH:

Due to the very small number of females diagnosed with HIV in rest of VCH residents, no stable trend in proportion is observed, and this should be interpreted with caution.

Table 5, 6. Proportion of HIV positives by Gender, Exposure and Year of Diagnosis

Vancouver HSDA (Table 5):

More new diagnoses were seen among males with MSM exposure in 2014-2015 compared to all other exposure groups. The proportion of new diagnoses among MSM has increased since 2003-2005, while those with IDU exposure and heterosexual exposure has declined.

The proportion of females with IDU exposure decreased in 2014-2015 compared to previous years and females with heterosexual exposure decreased compared to 2010-2013.

Rest of VCH (Table 6):

For males, the proportion of new diagnoses among MSM in 2014-2015 has declined since 2010-2013, while those with heterosexual exposure have increased.

Due to the very small number of females diagnosed with HIV in rest of VCH residents, no stable trend in proportion is observed, and this should be interpreted with caution.

Figure 5, 6. Number and Proportion of Patients' CD4 Cell Count and Disease Stage at Diagnosis by Year of Diagnosis

In the second half of 2015, the number of patients newly diagnosed with HIV is the same as the number diagnosed in the second half of 2014. There is an overall declining trend in number of new positives since 2003(Figure 5).

In the second half of 2015, the proportion of new diagnoses with a CD4 count > 500 or acute stage disease at time of diagnosis increased to the highest proportion ever observed with 59%. Furthermore, a decrease in the proportion of HIV patients diagnosed with a CD4 count <200 cells/mm³ in the second half of 2015 was observed compared to the preceding period (Figure 6).

Figure 7. Proportion and Ratio of Patients Diagnosed with CD4 > 500/Acute Stage and CD4 < 200 by Year of Diagnosis

The proportion of patients diagnosed with a CD4 count <200 cells/mm³ in 2015 is slightly higher than the proportion in 2014, but is still following a downward trend observed since 2006. The proportion of patients diagnosed with CD4 counts>=500 cells/mm³ or diagnosed at acute stage decreased slightly compared to 2014 although an increasing trend is observed since 2006. Therefore, the ratio of those diagnosed with a CD4>500/acute stage vs. a CD4 < 200 in 2015 (3.2: 1) is slightly less than the peak ratio observed in 2014 (3.6:1).

Maps 4, 5. Median CD4 Cell Count (cells/mm³) at diagnosis for HIV positive individuals

Compared to the historical baseline (Map 4), the median CD4 cell count at diagnosis has declined for residents of Richmond and Coastal Rural HSDAs as well as Vancouver South LHAs since the STOP initiative. Meanwhile the median CD4 cell count at diagnosis has increased in Coastal Urban HSDA and Vancouver City Centre, Vancouver DTES, Vancouver Northeast, Vancouver Westside, and Vancouver Midtown LHAs. (Map 5).



Figure 1. Number and Percent Positivity of HIV POC Tests








Table 1. Number of HIV Lab Tests by HSDA/LHA of Testing Clinic



How you want to be treated.

Desien		Cou	nts			OP HIV/AI 1, 2010 to			torical Base 008 to Jun 3		Year t	o Date	Significance
Region	Jul-Dec 2015	Jan-Jun 2015	Jul-Dec 2014	Jan-Jun 2014	Avg	Min	Max	Avg	Min	Max	Year 2015	Year 2014	Significance
Richmond	10235	10807	10594	8599	5569	2350	10807	2330	2228	2421	21042	19193	S+H+
Coastal Urban	8977	8605	7127	5467	4936	3053	8977	2975	2898	3104	17582	12594	S+H+Y+
LHA 44 North Vancouver	7529	7328	5989	4334	4046	2485	7529	2364	2341	2421	14857	10323	S+H+Y+
LHA45 West Vancouver- Bowen Island	1448	1277	1138	1133	890	568	1448	611	553	683	2725	2271	C+S+H+Y+
Coastal Rural	4423	4171	4195	3167	2686	1634	4423	1661	1619	1731	8594	7362	S+H+Y+
LHA 46 Sunshine Coast	1025	1238	1187	925	720	398	1238	400	375	438	2263	2112	S+H+
LHA 47 Powell River	1364	1111	1526	892	666	309	1526	309	296	333	2475	2418	C+S+H+
LHA 48 Howe Sound	1833	1634	1337	1171	1160	782	1833	853	815	903	3467	2508	C+S+H+Y+
LHA 49 Bella Coola Valley	121	121	100	113	85	60	121	50	37	63	242	213	S+H+Y+
LHA 83 Central Coast	80	67	45	66	56	40	80	49	43	58	147	111	C+S+H+Y+
Vancouver	74133	75100	69500	66340	54244	30286	75100	29286	28455	30443	149233	135840	S+H+
LHA 161 City Centre	49944	50564	46229	43288	35115	18194	50564	17154	16334	18207	100508	89517	S+H+Y+
LHA 162 DTES	4083	3802	3820	4047	3701	2812	4274	2729	2519	3029	7885	7867	S+H+
LHA 163 North East	3438	3412	3368	3676	2896	1630	3676	1685	1599	1724	6850	7044	S+H+
LHA 164 Westside	6092	6562	6530	6082	5048	3254	6562	3138	3070	3210	12654	12612	S+H+
LHA 165 Midtown	6263	6294	5098	4745	4048	2480	6294	2643	2480	2754	12557	9843	S+H+Y+
LHA 166 South	4313	4466	4455	4502	3436	1865	4508	1938	1799	2038	8779	8957	S+H+
Total	97772	98689	91422	83575	67453	37475	98689	36410	35560	37579	196461	174997	S+H+Y+

Source: Provincial Public Health Microbiology and Reference Laboratory (Misys Laboratory Database) & Providence Health Care Virology Laboratory. Prepared by: Vancouver Coastal Health, Public Health Surveillance Unit. April 12, 2016.





24


Vancouver CoastalHealth Promoting wellness. Ensuring care.

Mean Monthly HIV Lab Tests per 10,000 Population by LHA










25



Figure 2. Number and Percent Positivity of HIV Lab Tests among VCH Residents






Source: Public Health Surveillance Unit (HIV Surveillance Data, Provincial Public Health Microbiology and Reference Laborato (Misys Laboratory Database) & Providence Health Care Virology Laboratory Database. Prepared by: Vancouver Coastal Health, Public Health Surveillance Unit. April 12, 2016.

Public Health Surveillance Unit



Figure 3. Number and Percent Positivity of HIV Lab Tests among VCH Residents by HSDA





Note: Axis values are not equal across all graphs. Compare test volumes with caution.

Source: Public Health Surveillance Unit (HIV Surveillance Data, Provincial Public Health Microbiology and Reference Laboratory (Misys Laboratory Database) & Providence Health Care Virology Laboratory Database.





Table 2. Monthly Average of HIV Lab Tests, Population Rate of HIV Lab Tests, HIV Positives and Percent Positivity among VCH Residents by HSDA/LHA



Promoting wellness. Ensuring care.

		HIV Lab Tests		HIV Lab T	ests per 10,000 pop	pulation	P	ositive HIV Lab Test	s		Percent Positivity	
Region	Stop Expansion (Apr 2013 to date)	STOP Pilot (July 2010- Mar 2013)	Historical (Jan 2008- Jun 2010)	Stop Expansion (Apr 2013 to date)	STOP Pilot (July 2010- Mar 2013)	Historical (Jan 2008- Jun 2010)	Stop Expansion (Apr 2013 to date)	STOP Pilot (July 2010- Mar 2013)	Historical (Jan 2008- Jun 2010)	Stop Expansion (Apr 2013 to date)	STOP Pilot (July 2010- Mar 2013)	Historical (Jan 2008- Jun 2010)
Richmond	1051	508	427	52.6	25.6	22.2	0.4	0.5	0.5	0.04	0.1	0.1
Coastal Urban	545	456	433	27.6	23.2	22.8	0.2	0.2	0.3	0.03	0.05	0.1
LHA 44 North Vancouver	604	440	396	41.9	30.7	28.6	0.2	0.2	0.5	0.03	0.05	0.1
LHA45 West Vancouver- Bowen Island	209	141	117	39.2	26.6	22.8	0.2	0.2	0.0	0.1	0.2	0.03
Coastal Rural	836	605	566	89.9	65.7	64.2	0.3	0.2	0.1	0.04	0.04	0.02
LHA 46 Sunshine Coast	122	82	71	39.9	27.0	24.1	0.0	0.0	0.1	0.02	0.04	0.1
LHA 47 Powell River	146	38	33	72.3	19.1	16.5	0.2	0.0	0.0	0.1	0.1	0.0
LHA 48 Howe Sound	265	136	96	70.2	36.6	27.7	0.1	0.1	0.0	0.05	0.1	0.03
LHA 49 Bella Coola Valley	14	10	7	47.2	32.2	22.4	0.0	0.0	0.0	0.0	0.0	0.0
LHA 83 Central Coast	13	8	7	84.6	54.2	47.8	0.0	0.1	0.0	0.0	0.7	0.0
Vancouver	4611	3382	2536	67.4	50.2	39.6	8.9	9.0	11.9	0.2	0.3	0.5
LHA 161 City Centre	1068	870	668	86.3	71.2	56.5	2.9	3.2	4.2	0.3	0.4	0.6
LHA 162 DTES	733	547	378	101.1	76.4	58.8	1.9	1.5	1.9	0.3	0.3	0.5
LHA 163 North East	559	415	328	51.4	38.6	31.5	0.6	0.8	0.7	0.1	0.2	0.2
LHA 164 Westside	817	571	438	58.0	41.1	32.9	0.4	0.5	0.4	0.1	0.1	0.1
LHA 165 Midtown	677	485	364	67.8	50.0	41.5	0.7	0.7	0.6	0.1	0.1	0.2
LHA 166 South	754	493	358	54.2	35.9	26.8	0.5	0.7	0.7	0.1	0.1	0.2
Total*	7312	5076	4042	62.2	43.7	36.4	10.1	10.2	13.1	0.1	0.2	0.3

*Total may not equal to sum of all LHAs due to missing assignment of LHA coding in original data.

Source: Public Health Surveillance Unit (HIV Surveillance Data), Provincial Public Health Microbiology and Reference Laboratory (Misys

Laboratory Database) & Providence Health Care Virology Laboratory.





Gender Male

Female

60+

Subtotal*

Table 3. Percent Positivity among Vancouver Residents by Gender and Age Group



Promoting wellness. Ensuring care.

• Aco	Current Half-Year	Previous I	Half-Years	STOP HIV-AIDS	Historical Baseline	Year t	o Date
r Age	Jul 2015-Dec 2015	Jan 2015-Jun 2015	Jul 2014-Dec 2014	Jul 2010- Dec 2015	Jan 2008-Jun 2010	2015	2014
0-9	0.00	0.00	0.00	0.00	0.00	0.00	0.00
10-19	0.00	0.00	0.00	0.21	0.15	0.00	0.00
20-29	0.44	0.67	0.33	0.58	0.84	0.56	0.66
30-39	0.18	0.34	0.45	0.60	1.15	0.26	0.60
40-49	0.21	0.62	0.41	0.69	1.61	0.41	0.45
50-59	0.29	0.40	0.41	0.45	0.88	0.35	0.44
60+	0.09	0.06	0.02	0.11	0.44	0.07	0.08
Subtotal*	0.21	0.34	0.27	0.46	1.05	0.28	0.39
e 0-9	0.00	0.00	0.00	0.00	0.00	0.00	0.00
10-19	0.00	0.00	0.00	0.00	0.16	0.00	0.00
20-29	0.06	0.00	0.03	0.04	0.07	0.03	0.02
30-39	0.12	0.05	0.05	0.05	0.08	0.08	0.04
40-49	0.09	0.00	0.05	0.08	0.15	0.05	0.08
50-59	0.06	0.06	0.00	0.04	0.44	0.06	0.04

0.02

0.04

0.11

0.10

0.01

0.04

*Subtotal may not equal to sum of all LHAs due to missing values in the original data.

0.02

0.02

0.00

0.06

Source: Public Health Surveillance Unit (HIV Surveillance Data), Provincial Public Health Microbiology and Reference Laboratory (Misys Laboratory Database) & Providence Health Care Virology Laboratory.

0.00

0.03

Prepared by: Vancouver Coastal Health, Public Health Surveillance Unit. April 12, 2016.



0.02

0.03



Table 4. Percent Positivity among<u>Rest of VCH</u> Residents by Gender and Age Group



How you want to be treated.

Canadan	A = 4	Current Half-Year	Previous I	Half-Years	STOP HIV-AIDS	Historical Baseline	Year t	o Date
Gender	Age	Jul 2015-Dec 2015	Jan 2015-Jun 2015	Jul 2014-Dec 2014	Jul 2010- Dec 2015	Jan 2008-Jun 2010	2015	2014
Male	0-9	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	10-19	0.00	0.00	0.00	0.06	0.13	0.00	0.00
	20-29	0.07	0.07	0.00	0.10	0.09	0.07	0.00
	30-39	0.14	0.20	0.31	0.13	0.07	0.17	0.21
	40-49	0.07	0.00	0.00	0.11	0.33	0.04	0.04
	50-59	0.20	0.00	0.14	0.17	0.18	0.10	0.12
	60+	0.00	0.03	0.00	0.05	0.21	0.02	0.02
	Subtotal*	0.08	0.06	0.07	0.10	0.15	0.07	0.07
Female	0-9	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	10-19	0.00	0.00	0.00	0.00	0.00	0.00	0.00
	20-29	0.00	0.00	0.00	0.00	0.01	0.00	0.00
	30-39	0.00	0.00	0.09	0.02	0.02	0.00	0.07
	40-49	0.00	0.06	0.00	0.03	0.09	0.03	0.00
	50-59	0.00	0.07	0.00	0.04	0.07	0.03	0.04
	60+	0.03	0.00	0.00	0.01	0.00	0.02	0.00
	Subtotal*	0.01	0.02	0.02	0.01	0.03	0.01	0.02

*Subtotal may not equal to sum of all LHAs due to missing values in the original data.


Source: Public Health Surveillance Unit (HIV Surveillance Data), Provincial Public Health Microbiology and Reference Laboratory (Misys Laboratory Database) & Providence Health Care Virology Laboratory.





Figure 4. Proportion of New HIV Positives by Gender and Year of Diagnosis and Males/Females Ratio by Year of Diagnosis







Source: Public Health Surveillance Unit (HIV Surveillance Data).





Table 5. Proportion of HIV PositivesBy Gender, Exposure and Year of Diagnosis(Vancouver HSDA)



Candan	F		Year of Diag	nosis	
Gender	Exposure	2003-2005	2006-2009	2010-2013	2014-2015
Male	MSM	62.6	68.9	73.9	74.0
	MSM/IDU	5.6	4.1	2.7	1.3
	IDU	17.3	12.4	7.0	6.3
	Heterosexual	12.9	11.3	9.9	7.6
	Other*	1.4	1.7	0.6	3.1
	Unknown	0.2	1.7	5.8	7.6
Female	IDU	61.6	48.9	30.9	20.0
	Heterosexual	34.9	46.7	65.5	40.0
	Other*	3.5	3.3	1.8	8.0
	Unknown	0.0	1.1	1.8	32.0



 Table 6. Proportion of HIV Positives

 by Gender, Exposure and Year of Diagnosis

 (Rest of VCH)



Year of Diagnosis Exposure Gender 2003-2005 2006-2009 2010-2013 2014-2015 Male MSM 53.2 60.5 64.7 50.0 IDU 12.8 11.6 3.9 0.0 Heterosexual 27.7 20.9 19.6 33.3 Other* 4.3 7.0 2.0 4.2 Unknown 0.0 9.8 2.1 12.5 Female IDU 22.2 12.5 28.6 0.0 Heterosexual 66.7 87.5 42.9 71.4 Other* 11.1 0.0 28.6 0.0

*Other includes blood/blood products, occupational, perinatal and other exposures


Source: Public Health Surveillance Unit (HIV Surveillance Data).





Figure 5. Number of Patients' CD4 Cell Count and Disease Stage at Diagnosis by Year of Diagnosis






Source: Public Health Surveillance Unit (HIV Surveillance Data) & BC CfE Drug Treatment Program Data. Prepared by: Vancouver Coastal Health, Public Health Surveillance Unit. April 12, 2016.






Figure 6. Proportion of Patients' CD4 Cell Count and Disease Stage at Diagnosis by Year of Diagnosis






Source: Public Health Surveillance Unit (HIV Surveillance Data) & BC CfE Drug Treatment Program Data. Prepared by: Vancouver Coastal Health, Public Health Surveillance Unit. April 12, 2016.









Source: Public Health Surveillance Unit (HIV Surveillance Data) & BC CfE Drug Treatment Program Data. Prepared by: Vancouver Coastal Health, Public Health Surveillance Unit. April 12, 2016.





Map 4. Historical half-year average

Map 5. Average since Stop initiative (July 2010 – December 2015)

Median CD4 Cell Count (cell/mm³) at Diagnosis for HIV Positive Individuals







Notes:

- Maps A and B report on median CD4 count at diagnosis by HSDA
- Map C reports on median CD4 count at diagnosis by LHA

Section 3. Public Health Management Indicators

Figures, Maps and Tables

Figure 8. Proportion of New Diagnoses with Records of Public Health Follow-up

Compared to the preceding half year, the proportion of new positives with a record of public health follow-up declined from 96% (S1 2015) to 83% (S2 2015). It is important to note that most cases who are residents of VCH that do not have a record of public health follow up were tested in a different health authority and therefore follow up will not be on record in VCH. Furthermore, it is important to note that the public health management indicators are based on the case diagnosis date and therefore are likely to change as follow-up is completed over time.

Figure 9. Total Number of Partners Elicited, Partners per HIV Case and Partners Notified

Compared to the preceding periods, there was a significant decrease in the total number of partners elicited from HIV index cases in the second half of 2015.

The proportion of all partners that were known to be notified of their exposure to HIV in the second half of 2015 is significantly higher than preceding periods.

Figure 10. Proportion of Known Partners and Average Number of Anonymous Partners per Index Case

In the second half of 2015, the proportion of known partners was higher compared to the previous period and a decrease was observed in the average number of anonymous partners per index case.


Figure 11. Number of Partners Notified and Tested for HIV and Percent Positivity due to Partner Notification

The total number of partners that were tested for HIV as a result of public health follow-up increased in the second half of 2015, compared to the preceding period. Six new positives were identified in the second half of 2015, yielding a percent positivity of 11% due to partner notification among partners tested for HIV.



Figure 8. Proportion of New Diagnoses with Records of Public Health Follow-up






Source: Enhanced HIV Contact Tracing Form. Prepared by: Vancouver Coastal Health, Public Health Surveillance Unit. April 12, 2016.





Figure 9. Total Number of Partners Elicited Number of Partners Elicited per Case and Number of Partners Notified






Source: Enhanced HIV Contact Tracing Form. Prepared by: Vancouver Coastal Health, Public Health Surveillance Unit. April 12, 2016





Figure 10. Proportion of Known Contacts and Average Number of Anonymous Contacts per Index Case





Source: Enhanced HIV Contact Tracing Form. Prepared by: Vancouver Coastal Health, Public Health Surveillance Unit. April 12, 2016






Figure 11. Number of Contacts Notified and Tested for HIV and

Percent Positivity due to Contact Tracing

Source: Enhanced HIV Contact Tracing Form. Prepared by: Vancouver Coastal Health, Public Health Surveillance Unit. April 12, 2016

Vancouver

CoastalHea

Public Health Surveillance Unit

Section 4. Treatment Indicators

Figures, Maps and Tables

Table 7,8. Proportion of Patients Linked to Care within 30 Days by Gender, Exposure and Year of Diagnosis

Vancouver HSDA (Table 7):

In 2014-2015, the proportion of males with IDU exposure linked to care within 30 days of diagnosis was highest among all exposure categories and continued to increase compared to previous years. The proportion of males with MSM exposure linked to care within 30 days also increased compared to previous years while males with heterosexual exposure declined. In the period of 2014-2015, time to linkage to care was longest among males with 'other' exposure, although the median days to linkage decreased in this group compared to previous years.

In 2014-2015, the proportion of females with IDU exposure linked to care within 30 days was highest among all exposure categories. The time to linkage to care overall was shorter among females.

Rest of VCH (Table 8):

The proportion of males with MSM exposure linked to care within 30 days of diagnosis increased in 2014-2015 compared to previous years. There were also slight decreases in time to linkage among those with MSM and heterosexual exposures compared to previous time periods.

The proportion of females linked to care within 30 days increased in 2014-2015 compared to previous years. However, not enough cases were available to detect a trend.

In general, linkage to care times in the rest of VCH are greater than median times to linkage in Vancouver across all exposure groups.

Table 9,10. Proportion of Patients Linked to Care within 30 Days by Gender, Age Group and Year of Diagnosis

Vancouver HSDA (Table 9):

Males aged 60-69 had the highest proportion linked to care within 30 days of diagnosis compared to all other age groups in 2014-2015, followed by males aged 30-39. Males aged 15-29 and 30-39 years had the fastest median days to linkage with 6 days, while males aged 60 years or older at diagnosis had the slowest median days to linkage with 12 days.

In 2014-2015, too few females were diagnosed to assess trend in proportion linked to care by age category. Overall, there is an increasing trend in the proportion linked to care as well as a reduction in the median days to linkage.

Rest of VCH (Table 10):

In 2014-2015, too few males were diagnosed to assess trend in proportion linked to care by age category. Overall, there is an increasing trend in proportion linked to care as well as a reduction in the median days to linkage.

There are not enough cases to classify by age group for females. But overall, an increase in the proportion of patients linked to care within 30 days was observed.

Table 11,12. Proportion of Patients Currently Retained in Care by Gender, Exposure and Year of Care

Vancouver HSDA (Table 11)

In 2015, among known exposure categories, males with MSM/IDU exposure had the highest proportion of individuals retained in care followed by heterosexuals. Since 2003, the total proportion of males retained in care remains steady.

In 2015, a greater proportion of females with heterosexual exposure were retained in care compared to those with IDU exposure.

Rest of VCH (Table 12)

In 2015, among known exposure categories, a greater proportion of males with MSM exposure were currently retained in care compared to other exposure groups.

The proportion of female patients in 2015 retained in care with heterosexual exposure decreased compared to 2014.

Table 13,14. Proportion of Patients Currently Prescribed ARVs by Gender, Exposure and Year of Care

Vancouver HSDA (Table 13)

In 2015, the exposure category with the greatest proportion of individuals currently prescribed ARVs was among MSM/IDU (79.7%) followed by heterosexual (74.6%). Compared to previous years, the proportion of males in all exposure categories, except those with unknown exposure, who were prescribed ARVs, has consistently increased since 2003.

The proportion of females with heterosexual exposure who were prescribed ARVs continued to increase through 2015.

Rest of VCH (Table 14)

Males with IDU exposure had the greatest proportion of individuals who were prescribed ARVs in 2015 (91.7%). Since 2003, the proportion of males who were prescribed ARVs has increased among those with MSM, IDU or heterosexual exposures.

Since 2004, the proportion of females who were prescribed ARVs increased from 29% to 75% in 2015.

Overall, there was an increasing trend in the proportion of males and females currently prescribed ARVs.

Table 15, 16. Mean Monitored Viral Load and Proportion of HIV Positive Individuals Not Fully Suppressed with Viral Load > 200 Copies/mL

Vancouver HSDA (Table 15)

The table shows a steady decline in the mean monitored viral load (copies/ml) since 2008 from 746 copies/ml to 57 copies/ml in the second half of 2015. This corresponds with a steady increase in the proportion of HIV positive individuals with a prescription for antiretroviral therapy. The inverse relationship was observed for decline in both the proportion and absolute number of individuals with a viral load > 200 copies/ml since 2008.

Rest of VCH (Table 16)

Similar to Vancouver HSDA, the same trends were observed in the rest of VCH with increasing individuals on ARVs and decreasing monitored viral load since 2008.

Figure 12. Mean Monitored Viral Load (copies/ml) and Proportion of HIV Positive Individuals not Fully Suppressed with Viral Load > 200 Copies/mL

From 2009 to 2015, the mean monitored viral load (copies/ml) has steadily declined in both Vancouver HSDA and the rest of VCH. This trend was similarly observed in the proportion of those with unsuppressed viral loads. The mean monitored viral load was below detectable levels (<200 copies/ml) since the initiation of STOP HIV/AIDS.

Maps 6, 7. Mean Monitored viral load (copies/ml) by LHAs

From July 1, 2010 to December 31, 2015, the mean monitored viral load across all LHAs decreased to less than 200 copies/mL. There were noticeable declines in mean monitored viral load for all LHAs except West Vancouver- Bowen Island.



Table 7. Proportion of Patients Linked to Care within 30 Days of Diagnosis by Gender, Exposure and Year of Diagnosis (Vancouver HSDA)



					Year of D	iagnosis			
Gender	Fynasia	2003	-2005	2006	-2009	2010	-2013	2014	-2015
Gender	Exposure	Linked to Care	Median Days to Linkage						
Male	MSM	57.2	14	63.9	12	73.4	9	76.4	6
	MSM/IDU	60.7	16	60.0	17	64.3	10	-	-
	IDU	43.0	13	61.3	12.5	72.2	6.5	85.7	7
	Heterosexual	60.9	13	72.1	9	94.1	7	76.5	7
	Other*	57.1	18.5	40.0	13	-	-	57.1	9.5
	Unknown	-	-	20.0	1	73.3	7	58.8	5
	SubTotal	55.3	14	63.2	12	74.9	8	75.3	7
Female	IDU	30.2	18.5	42.2	13	64.7	2	-	9
	Heterosexual	53.3	13	86.0	12	77.8	9	70.0	2
	Other*	_	_	_	_	_	-	_	-
	Unknown	_	-	_	-	_	-	-	12
	SubTotal	39.5	14	63.0	12.5	74.5	9	76.0	3

Table 8. Proportion of Patients Linked to Care within 30 Days of Diagnosis by Gender, Exposure and Year of Diagnosis (rest of VCH)

					Year of D	Diagnosis			
Condon	Fundation	2003	-2005	2006	-2009	2010	-2013	2014	4-2015
Gender	Exposure	Linked to Care	Median Days to						
		LINKEU to Care	Linkage	LINKEU to Care	Linkage	LINKED to Care	Linkage		Linkage
Male	MSM	64.0	20	46.2	13.5	78.8	11.5	83.3	10.5
	IDU	33.3	9.5	40.0	13	-	-	-	-
	Heterosexual	53.8	13	55.6	14	80.0	16	75.0	13
	Other*	-	-	-	-	-	-	-	-
	Unknown	-	-	-	-	60.0	0	-	-
	SubTotal	55.3	15	51.2	14	78.4	12.5	83.3	10.5
Female	IDU	-	-	-	-	-	-	-	-
	Heterosexual	66.7	22.5	85.7	12.5	-	-	100.0	13
	Other*	-	-	-	-	-	-	-	_
	Unknown	-	-	-	-	-	-	-	-
	SubTotal	66.7	22.5	75.0	12.5	85.7	16	100.0	10

*Other includes blood/blood products, occupational, perinatal and other exposures Source: Public Health Surveillance Unit (HIV Surveillance Data).

Prepared by: Vancouver Coastal Health, Public Health Surveillance Unit. April 12, 2016.





Table 9. Proportion of Patients Linked to Care within 30 Days of Diagnosis by Gender, Age Group and Year of Diagnosis (Vancouver HSDA)



			Year of Diagnosis										
Condon	Area Caravan	2003	-2005	2006	-2009	2010	-2013	2014	-2015				
Gender	Age Group	Linked to Care	Median Days to Linkage										
Male	15-29	43.0	19.0	55.8	13.0	66.9	9.0	75.8	6.0				
	30-39	56.3	14.0	60.1	13.0	68.2	9.0	80.0	6.0				
	40-49	53.8	13.5	64.4	11.0	83.0	7.0	70.5	7.0				
	50-59	64.1	12.0	75.7	12.0	80.6	7.0	71.4	7.0				
	60+	74.1	13.0	83.3	8.0	100.0	9.5	81.3	12.0				
	SubTotal	55.3	14.0	63.2	12.0	74.9	8.0	75.3	7.0				
Female	15-29	38.5	11.0	39.4	11.0	66.7	13.0	-	1.5				
	30-39	56.5	18.0	72.4	14.0	73.3	1.0	63.6	9.0				
	40-49	25.9	15.0	78.6	19.0	73.3	7.0	83.3	3.0				
	50-59	40.0	21.0	77.8	7.0	100.0	12.5	-	2.0				
	60+	#VALUE!		80.0	6.5	-	-	-	7.5				
	SubTotal	38.8	14.0	62.2	12.5	74.5	9.0	76.0	3.0				

Table 10. Proportion of Patients Linked to Carewithin 30 Days of Diagnosis by Gender, AgeGroup and Year of Diagnosis (*rest of VCH*)

		Year of Diagnosis										
Condon	Ago Crown	2003	-2005	2006	-2009	2010	-2013	2014-2015				
Gender	Age Group	Linked to Care	Median Days to Linkage	Linked to Care	Median Days to Linkage	Linked to Care	Median Days to Linkage	Linked to Care	Median Days to Linkage			
Male	15-29	57.1	25.0	50.0	14.0	71.4	14.5	-	13.0			
	30-39	40.0	10.5	55.6	16.0	66.7	8.5	80.0	7.5			
	40-49	65.0	13.0	41.2	12.0	83.3	13.5	-	4.0			
	50-59	40.0	22.0	42.9	13.0	85.7	12.5	83.3	12.0			
	60+	60.0	22.0	_	_	80.0	11.0	-	6.0			
	SubTotal	55.3	15.0	51.2	14.0	78.4	12.5	83.3	10.5			
Female	15-29	-	-	-	-	-	-	-	-			
	30-39	-	-	-	-	-	-	-	-			
	40-49	-	-	-	-	-	-	-	-			
	50-59	-	-	-	-	-	-	-	-			
	60+	_	_	_	_	_	_	-	-			
	SubTotal	62.5	22.0	75.0	12.5	85.7	16.0	100.0	10			

*Other includes blood/blood products, occupational, perinatal and other exposures

*Individual Aged less than 14 was excluded from the table

Source: Public Health Surveillance Unit (HIV Surveillance Data).

Prepared by: Vancouver Coastal Health, Public Health Surveillance Unit. April 12, 2016.





 Table 11. Proportion of Patients Currently Retained in Care

 by Gender, Exposure and Year of Care (Vancouver HSDA)



Candan	Exposure							Year of Care						
Gender	Exposure	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015
Male	MSM	92.3	86.4	83.2	81.0	82.4	81.1	79.7	82.1	81.8	82.4	81.5	80.5	77.4
	MSM/IDU	-	61.5	80.0	76.5	75.0	78.6	81.8	86.7	85.7	83.0	87.5	86.0	84.7
	IDU	69.2	72.1	70.1	62.4	71.8	76.1	77.1	76.1	78.0	78.6	76.4	75.5	74.5
	Heterosexual	100.0	66.7	78.4	71.7	76.3	78.5	78.6	83.8	84.2	84.1	82.7	83.2	83.4
	Other*	-	-	80.0	87.5	66.7	44.4	45.5	61.5	69.2	66.7	73.3	66.7	72.2
	Unknown	_	-	-	-	_	_	-	71.4	71.4	71.4	77.8	91.2	89.5
	Subtotal	90.1	78.6	79.9	76.6	79.3	79.5	78.7	81.3	81.5	81.9	81.2	80.6	78.3
Female	IDU	66.7	66.7	55.3	57.7	56.1	60.8	68.8	73.4	79.3	80.7	79.8	78.2	81.8
	Heterosexual	83.3	64.3	85.0	78.6	80.0	84.3	79.3	78.3	79.0	90.0	84.0	83.7	86.6
	Other*	_	-	-	-	_	_	100.0	83.3	100.0	83.3	100.0	100.0	83.3
	Subtotal	75.0	67.6	66.7	65.1	66.1	71.1	74.3	76.0	79.9	85.5	82.6	81.8	84.1

Table 12. Proportion of Patients Currently Retained in Care by Gender, Exposure and Year of Care (rest of VCH)

.	Exposuro	Year of Care												
Gender	Exposure	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015
Male	MSM	_	84.6	72.7	85.2	79.4	82.5	83.3	86.0	81.0	84.3	83.3	85.1	86.3
	IDU	_	_	80.0	50.0	50.0	63.6	80.0	80.0	60.0	75.0	83.3	81.8	81.8
	Heterosexual	-	100.0	77.8	80.0	66.7	91.7	93.8	83.3	85.7	68.2	87.0	81.5	82.8
	Other*	-	-	-	-	-	-	-	-	-	-	_	_	_
	Unknown	_	_	-	_	_	-	_	_	_	_	_	100.0	100.0
	Subtotal	100.0	86.4	75.7	79.5	71.7	81.3	85.5	85.0	80.2	80.2	84.8	84.9	86.2
Female	IDU	-	_	-	-	-	-	-	-	-	-	_	_	_
	Heterosexual	-	_	60.0	66.7	66.7	90.0	84.6	92.9	78.6	78.6	81.3	72.2	76.2
	Other*	_	_	-	_	_	_	_	_	_	_	_	_	_
	Subtotal	_	60.0	62.5	66.7	72.7	91.7	87.5	89.5	84.2	84.2	87.0	76.0	75.9

*Other includes blood/blood products, occupational, perinatal and other exposures.

Source: Public Health Surveillance Unit (HIV Surveillance Data) & BCCfE Drug Treatment Program Data. Prepared by: Vancouver Coastal Health, Public Health Surveillance Unit. April 12, 2016.

49



Table 13. Proportion of Patients Currently Prescribed ARVs by Gender, Exposure and Year of Care (Vancouver HSDA)



Candan	F	Year of Care												
Gender	Exposure	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015
Male	MSM	17.9	22.7	28.3	30.7	37.0	42.6	50.7	58.0	62.6	66.3	59.6	64.8	67.7
	MSM/IDU	14.3	11.1	17.9	28.2	33.3	45.5	53.1	66.7	70.2	72.9	68.8	75.0	79.7
	IDU	5.6	19.4	22.7	33.0	37.4	43.9	50.3	55.8	62.2	67.1	64.2	66.5	74.0
	Heterosexual	32.3	34.0	38.1	43.8	49.5	58.1	60.0	62.6	69.2	70.7	64.3	67.0	74.6
	Other*	-	-	40.0	45.5	53.8	43.8	50.0	54.5	58.3	56.0	51.5	57.6	66.7
	Unknown	-	40.0	60.0	60.0	57.1	45.9	46.9	57.6	56.5	55.6	42.8	55.2	55.9
	Subtotal	17.9	23.2	28.7	33.4	39.2	44.9	51.6	58.5	63.2	66.4	59.3	64.6	68.4
Female	IDU	0.0	8.6	9.1	10.1	18.8	25.3	33.7	43.9	58.8	62.6	62.5	65.4	67.3
	Heterosexual	20.0	12.5	19.4	25.6	29.3	42.4	46.1	52.3	62.0	66.4	68.3	70.8	76.7
	Other*	-	-	-	-	-	85.7	77.8	80.0	80.0	90.0	90.0	90.0	90.0
	Unknown	-	—	-	-	—	—	—	40.0	42.9	50.0	26.3	36.8	57.9
	Subtotal	11.1	11.3	13.5	17.2	24.8	35.1	41.4	49.2	60.7	65.2	63.6	66.8	71.9

Table 14. Proportion of Patients Currently Prescribed ARVs by Gender, Exposure and Year of Care (rest of VCH)

			Year of Care												
Gender	Exposure	2003	2004	2005	2006	2007	2008	2009	2010	2011	2012	2013	2014	2015	
Male	MSM	50.0	27.8	34.6	37.5	46.5	52.1	62.3	61.5	68.0	75.6	63.9	71.1	80.4	
	MSM/IDU	_	-	_	-	-	_	_	_	_	_	-	_	_	
	IDU	_	-	33.3	28.6	27.3	63.6	90.9	81.8	91.7	92.3	91.7	83.3	91.7	
	Heterosexual	-	12.5	18.2	45.5	41.7	62.5	73.7	69.6	68.0	72.0	60.6	66.7	78.8	
	Other*	-	-	-	-	-	_	_	-	-	-	-	-	_	
	Unknown	-	-	-	-	-	33.3	57.1	50.0	57.1	66.7	64.7	64.7	70.6	
	Subtotal	35.3	27.3	29.2	38.2	41.4	53.7	67.0	64.2	68.6	74.8	64.4	69.9	79.1	
Female	IDU	_	-	_	-	-	-	-	_	-	-	_	_	-	
	Heterosexual	-	20.0	50.0	50.0	50.0	63.6	46.2	64.3	75.0	70.6	54.2	70.8	79.2	
	Other*	-	-	_	_	_	-	-	-	-	-	_	_	-	
	Unknown	_	-	-	-	-	_	_	_	_	_	16.7	33.3	33.3	
	Subtotal	_	28.6	44.4	45.5	46.2	66.7	50.0	61.9	73.9	68.0	52.8	66.7	75.0	

*Other includes blood/blood products, occupational, perinatal and other exposures

Source: Public Health Surveillance Unit (HIV Surveillance Data) & BCCfE Drug Treatment Program Data.

Prepared by: Vancouver Coastal Health, Public Health Surveillance Unit. April 12, 2016.



50



Table 15. Mean Monitored Viral Load and Proportion of HIV Positive Individuals Not Fully Suppressed with Viral Load > 200 Copies/mL (Vancouver HSDA)



Promoting wellness. Ensuring care.

		١	/CH53	VCH54						
Year	Half years	Mean Monitored vL (copies/mL)	Proportion on ARVs (%)	Proportion of all HIV positive individuals with viral load (>200 copies/mL)	Numerator/Denominator of VCH54	Proportion on ARVs (%)				
2008	Jan-Jun	746	56	59	(375/640)	29				
2008	July-Dec	581	61	53	(361/684)	30				
2009	Jan-Jun	370	66	49	(361/732)	34				
2009	July-Dec	313	70	44	(338/773)	35				
2010	Jan-Jun	248	76	40	(326/816)	43				
2010	July-Dec	213	77	37	(329/883)	43				
2011	Jan-Jun	148	84	31	(286/911)	51				
2011	July-Dec	126	86	30	(297/985)	58				
2012	Jan-Jun	107	89	25	(256/1028)	62				
2012	July-Dec	97	91	23	(246/1069)	64				
2013	Jan-Jun	89	92	22	(243/1117)	66				
2013	July-Dec	76	94	20	(224/1136)	72				
2014	Jan-Jun	73	94	18	(216/1188)	71				
2014	July-Dec	63	95	15	(187/1213)	74				
2015	Jan-Jun	63	97	15	(190/1243)	82				
	July-Dec	57	97	15	(187/1253)	84				

Source: Public Health Surveillance Unit (HIV Surveillance Data) & BCCfE Drug Treatment Program Data. Prepared by: Vancouver Coastal Health, Public Health Surveillance Unit. April 12, 2016.



		١	/СН53	VCH54						
Year	Half years	Mean Monitored vL (copies/mL)	Proportion on ARVs (%)	Proportion of all HIV positive individuals with viral load (>200 copies/mL)	Numerator/Denominator of VCH54	Proportion on ARVs (%)				
2008	Jan-Jun	956	58	62	(32/52)	31				
2008	July-Dec	408	67	49	(28/57)	39				
2009	Jan-Jun	303	76	47	(31/66)	52				
2009	July-Dec	184	79	39	(28/71)	54				
2010	Jan-Jun	148	78	34	(26/77)	42				
2010	July-Dec	154	78	32	(27/85)	41				
2011	Jan-Jun	114	83	32	(27/84)	56				
2011	July-Dec	132	80	35	(35/100)	49				
2012	Jan-Jun	124	86	32	(35/108)	63				
2012	July-Dec	76	93	21	(24/115)	75				
2012	Jan-Jun	76	92	20	(24/120)	67				
2013	July-Dec	81	93	20	(25/124)	72				
	Jan-Jun	56	95	16	(21/131)	86				
2014	July-Dec	58	95	17	(23/137)	83				
2015	Jan-Jun	56	95	14	(21/148)	76				
	July-Dec	48	98	13	(20/150)	85				

Table 16. Mean Monitored Viral Load and Proportion of HIV Positive Individuals NotFully Suppressed with Viral Load > 200 Copies/mL (*rest of VCH*)


Source: Public Health Surveillance Unit (HIV Surveillance Data) & BCCfE Drug Treatment Program Data.

Prepared by: Vancouver Coastal Health, Public Health Surveillance Unit. April 12, 2016.



Figure 12. Mean Monitored Viral Load (vL) and Proportion of HIV Positive Individuals Not Fully Suppressed with Viral Load > 200 Copies/mL





Source: Public Health Surveillance Unit (HIV Surveillance Data) & BCCfE Drug Treatment Program Data. Prepared by: Vancouver Coastal Health, Public Health Surveillance Unit. April 12, 2016.







Mean Monitored Viral Load (copies/ml) by Local Health Area



Map 6. Historical Average (January 2008 – June 2010)







Copyright © 2013 Vancouver Coastal Health, Public Health Surveillance Unit. Not for Commercial Use.

Appendix A. Indicator Definitions and Rationale

Testing Indicators

VCH 1. Number of Point of Care Tests

Total number of Point of Care HIV tests administered by all sites engaged in STOP HIV/AIDS memorandums of understanding (in a given time period).

Rationale: Point-of-Care testing allows rapid on-site assessment of potentially HIV positive individuals, it improves access to care which may lead to increased case-finding, and reduced number of individuals who are unaware of their HIV status.

Data Source: HIV Point-of-Care (POC) Data

VCH4a. Number of New Positive POC Tests

Number of unique individuals who have had a positive POC HIV test in a given time period.

Rationale: Assessment of this indicator provides a measure of the success of testing initiatives and activities under the STOP HIV/AIDS Pilot Project.

Additional Selection Criteria:

• Previous positives are excluded.

Data Source: HIV Point-of-Care (POC) Data

VCH8a. Overall number of HIV lab tests (either from VCH residents or those who tested at a VCH clinic)

Total number of HIV lab tests, either from VCH residents or a VCH clinic including non-VCH residents who test in VCH.

Rationale: A primary objective of the STOP HIV/AIDS project is to increase testing across VCH Region. Assessing this indicator over time will provide a picture of how STOP HIV/AIDS is influencing HIV testing among clinical practices.

Data Source: HIV Laboratory Testing Data

VCH8b: Number of HIV lab tests from all clinics in VCH and HSDAs

Total number of HIV lab tests ordered from a clinic in VCH and HSDAs.

Rationale: A primary objective of the STOP HIV/AIDS project is to increase testing across VCH Region. Assessing this indicator over time will provide a picture of how STOP HIV/AIDS is influencing HIV testing among clinical practices.

Additional Selection Criteria:

• HIV lab testing records without a known clinic address are excluded.

Data Source: HIV Laboratory Testing Data

VCH11a: Number of HIV lab tests from residents of VCH and HSDAs

Total number of HIV lab tests ordered from residents of Vancouver Coastal Health Authority.

Rationale: Often people from outside the Health Authority will visit VCH to undergo HIV testing, this indicator is a measure of the testing volumes among residents of this Health Authority.

Additional Selection Criteria:

• HIV lab testing records without available residency information are included.

Data Source: HIV Laboratory Testing Data

VCH11d: Number of HIV lab tests from non-residents of VCH who tested in VCH.

Total number of HIV lab tests ordered from non-residents of Vancouver Coastal Health Authority.

Rationale: Often people from outside the Health Authority will visit VCH to undergo HIV testing, this indicator will measure this trend.

Additional Selection Criteria:

• HIV lab testing records without available residency information are excluded.

Data Source: HIV Laboratory Testing Data

VCH13a. Number of positive HIV diagnoses for residents of VCH and HSDAs

Total number of new unique HIV positive diagnoses within VCH as a whole and each HSDA.

Rationale: Increased case finding to reduce the number of individuals who are unaware of their HIV positive status is a primary objective of the STOP HIV/AIDS pilot project. This indicator is a direct measure of the success of the project.

Additional Selection Criteria:

- Individuals who may have been previously HIV positive are excluded.
- Individuals who tested in VCH without residency information are included.

Data Source: PHSU Reportable HIV Surveillance Data

VCH14a. Percent positivity of residents of VCH and HSDAs

The proportion of positive individuals diagnosed per HIV lab test administered for VCH residents.

Rationale: Increased case finding to reduce the number of individuals who are unaware of their HIV positive status is a primary objective of the STOP HIV/AIDS pilot project. This indicator will measure if STOP HIV/AIDS is indeed finding these individuals.

Additional Selection Criteria:

- Individuals who may have been previously HIV positive are excluded.
- Individuals who tested in VCH without residency information are included.

Data Source: PHSU Reportable HIV Surveillance Data and HIV Laboratory Testing Data

VCH45a. Proportion of HIV patients with CD4 count > 500 cells/mL or acute stage at time of diagnosis

Proportion of individuals diagnosed HIV positive in a given time period who have a CD4 cell count of >500 cells/mL or acute stage at the time of diagnosis.

Rationale: Diagnosing individuals earlier on in the course of disease enables them to get on treatment earlier, improves patient quality of life and reduce the transmission in the community.

Analytical Definition

- Numerator: A subset of the denominator with a first CD4 cell count at diagnosis is >500 cells/mL or in acute stage.
- Denominator: All new HIV positive cases diagnosed in a given time period with a CD4 test on record.

Additional Selection Criteria:

- The CD4 count at time of diagnosis is selected from the testing which was closest to the diagnosis date. And testing should be within 1 year after diagnosis.
- CD4 testing records with either missing dates or missing values are excluded from this analysis.

Data Source: PHSU Reportable HIV Surveillance Data and BCCfE Drug Treatment Data.

VCH45b. Proportion of HIV patients with CD4 count < 200 cells/mL at diagnosis

Proportion of individuals diagnosed HIV positive in a given time period who have a CD4 cell count <200 cells/mL at the time of diagnosis.

Rationale: Finding HIV positive individuals before late stage is an important objective of the STOP HIV/AIDS program. Diagnosing individuals earlier on in the course of disease enables them to get on treatment earlier, and improves patient quality of life. It is also an indication that we are reducing the number of individuals in the population who are unaware of their HIV infection.

- Numerator: A subset of the denominator with a first CD4 cell count < 200 cell/mL at diagnosis and not at acute stage at time of diagnosis.
- Denominator: All new HIV positive cases diagnosed in a given time period with a CD4 test on record.

Additional Selection Criteria:

- The CD4 count at time of diagnosis is selected from the value on the testing date which was closest to the diagnosis. The test should also be within 1 year after diagnosis.
- CD4 testing records with either missing dates or missing values are excluded from this analysis.

Data Source: PHSU Reportable HIV Surveillance Data and BCCfE Drug Treatment Data.

Public Health Management Indicators

VCH16. Proportion of new positives with record of public health follow-up

The proportion of unique new positives who have documentation of public health follow-up

Rationale: Contact tracing aims to reduce transmission of HIV, and is also effective in reducing the incidence of HIV in the population. This is an important public health strategy to reach individuals who may not be aware of their HIV status. Initiating contact tracing is to elicit partner information from an index case is a critical first step and will be important to track STOP HIV/AIDS success.

Data Source: PHSU Reportable HIV Surveillance Data and Enhanced HIV Contact Tracing Form

VCH17. Number of contacts elicited

Total number of unique contacts elicited from HIV positive clients in a given time period.

Rationale: see VCH16.

Data Source: PHSU Reportable HIV Surveillance Data and Enhanced HIV Contact Tracing Form

VCH17a. Average number of contacts elicited per HIV positive case

Average number of unique contacts elicited per HIV positive client in a given time period.

Rationale: see VCH16

Analytical Definition

- Numerator: Total number of unique contacts elicited in a given time period (VCH17)
- Denominator: Total number of unique HIV index cases of all contacts elicited in the given time period.

Data Source: PHSU Reportable HIV Surveillance Data and Enhanced HIV Contact Tracing Form

VCH19. Proportion of contacts notified

Proportion of unique contacts notified of their potential exposure to HIV in a given time period.

Rationale: Managing infection in people with more than one current sexual partner will have a significant impact on the spread of HIV, thus assessing the success of partner notification practice will be an important measure. Moreover, evidence suggests that the method of partner notification is associated with the rate of partners presenting for medical evaluation.

Analytical Definition

- Numerator: Total number of unique contacts notified in a given time period.
- Denominator: Total number of unique contacts elicited from HIV positive clients in a given time period.

Data Source: PHSU Reportable HIV Surveillance Data and Enhanced HIV Contact Tracing Form

VCH23a. Proportion of notified contacts tested for HIV

Proportion of Contacts tested for HIV in a given time period.

Rationale: The goal of contact tracing is to inform contacts of their risk of infection, encourage contacts to be tested for HIV and identify individuals who are HIV positive. This indicator will be an important measure of the success of the enhanced public health efforts under STOP HIV/AIDS pilot project.

Analytical Definition

- Numerator: Number of contacts tested for HIV in a given time period.
- Denominator: Number of contacts notified of their potential exposure to HIV.

Additional Selection Criteria:

• Contacts known to be previously positive are excluded.

Data Source: PHSU Reportable HIV Surveillance Data and Enhanced HIV Contact Tracing Form

VCH23b. Number of notified contacts who tested HIV positive

Number of contacts who tested HIV positive in a given time period.

Rationale: A second measure of case-finding and contact tracing success is identifying individuals who are HIV positive.

Additional Selection Criteria:

• Contacts known to be previously positive are excluded.

Data Source: PHSU Reportable HIV Surveillance Data and Enhanced HIV Contact Tracing Form

VCH23c. Percent positivity (%) due to Contact Tracing

The proportion of positive contacts diagnosed per contact tested for HIV.

Rationale: A second measure of case-finding and contact tracing success is identifying individuals who are HIV positive, and the yield of positive cases from these efforts.

Analytical Definition

- Numerator: Number of unique contacts tested for HIV who tested positive
- Denominator: Proportion of contacts tested for HIV in a given time period

Additional Selection Criteria:

• Exclude contacts known to be previously positive.

Data Source: PHSU Reportable HIV Surveillance Data and Enhanced HIV Contact Tracing Form

VCH24. Proportion of notified contacts who were known to be previously positive

Proportion of contacts who were previously positive in a given time period.

Rationale: Identifying partners in the latent period of infection may identify those from whom infection was acquired, but overall this indicator will provide a picture of the HIV population in VCHA.

Analytical Definition

- Numerator: Number of contacts known/determined to be previously positive in a given time period.
- Denominator: Proportion of unique contacts notified of their potential exposure to HIV in a given time period.

Data Source: PHSU Reportable HIV Surveillance Data and Enhanced HIV Contact Tracing Form

Treatment Indicators

VCH41. Proportion of new diagnoses linked to care within 30 days of diagnosis

Proportion of individuals with an HIV positive test in a given time period, who have at least a HIV viral load (vL) or a CD4 test on record within 30 days of diagnosis.

Rationale: It is vital that linkage to HIV-care occur as soon after diagnosis as possible so that a clinical evaluation can be conducted, eligibility for ARV therapy and linkage to other services can be established to minimize the risk of transmission. Standard care for persons with HIV includes regular clinical and laboratory assessment. As part of enhanced HIV guidelines, new HIV diagnoses should receive a vL test or a CD4 test within 30 days of diagnosis.

- Numerator: A subset of the denominator having a CD4 or a vL test within 30 days of diagnosis.
- Denominator: Total number of new HIV positive cases diagnosed in a given time period.

Additional Selection Criteria:

- CD4 and/or vL testing records that occurred prior to diagnosis date are excluded from this analysis.
- Individuals deceased by the end of the half year are excluded.
- CD4 or viral load testing records with either missing dates or missing values are excluded from this analysis.

Data Source: PHSU Reportable HIV Surveillance Data and BCCfE Drug Treatment Data.

VCH44b. Time to linkage to HIV care among those newly diagnosed with HIV (median days).

The interval between first HIV positive test and first HIV CD4 or viral load, among all individuals diagnosed in the given time period.

Rationale: It is vital that linkage to HIV-care occur as soon after diagnosis as possible so that a clinical evaluation can be conducted, eligibility for ARV therapy and linkage to other services can be established to minimize the risk of transmission. Standard care for persons with HIV includes regular clinical and laboratory assessment. As part of enhanced HIV guidelines, new HIV diagnoses should receive a vL test or a CD4 test within 30 days of diagnosis. This indicator provides a picture of how quickly HIV positive individuals are in fact receiving the appropriate care.

Additional Selection Criteria:

- CD4 or viral load testing records that occurred prior to diagnosis date are excluded from this analysis.
- Individuals deceased by the end of the half year are excluded.
- CD4 or viral load testing records with either missing dates or missing values are excluded from this analysis.

Data Source: PHSU Reportable HIV Surveillance Data and BCCfE Drug Treatment Data.

VCH46a. Proportion of HIV patients currently retained in care

Proportion of HIV positive individuals in the database who have had the recommended number of vL tests in a given time period.

Rationale: Because HIV disease progression is highly variable and can occur rapidly, and treatment requires constant evaluation for efficacy and safety, HIV patients need to be closely monitored on a regular basis. Standard practice requires a minimum of 3 visits/laboratory assignments annually.

- Numerator: Total number of newly diagnosis cases who having at least 2 vL or CD4 test and with at least 3 month apart in a year, or at least 1 vL or CD4 test for those diagnosed less than 1 year.
- Denominator: Total number of newly diagnosis in the dataset.
- Year to Date: take the value from the current half-year and previous half-year.

Additional Selection Criteria:

- This cohort will retrospectively select back over the past 12 months.
- Only individuals linked with BCCfE Drug Treatment Data are included.
- Individuals without any CD4 or vL test since diagnosis are excluded.
- Individuals diagnosed less than half year for a given time period are excluded.
- Individuals deceased before the end of a given time period are excluded.
- CD4 and Viral load testing records that occurred prior to diagnosis date are excluded from this analysis.
- CD4 and Viral load testing records with either missing dates or missing values are excluded from this analysis.

Data Source: PHSU Reportable HIV Surveillance Data and BCCfE Drug Treatment Data.

VCH47b. Proportion of matched HIV patients not found in care

Proportion of all known HIV positive individuals in the population who have been diagnosed for at least 9 months, and have not had a vL test within the past 9 months.

Rationale: Due to the need for long-term monitoring of both disease progression and the efficacy of any therapy, as well as the status of comorbid conditions or lifestyle factors, long-term retention in HIV-related care is imperative to minimize the risk of HIV-related morbidity and mortality.

Analytical Definition

- Numerator: Number of HIV patients in the denominator who have not had a vL for at least 9 months
- Denominator: All individuals in the dataset who have been HIV positive for at least 9 months.
- Year to Date: take the value from the current half-year and previous half-year.

Additional Selection Criteria:

- Only individual linked with BCCfE Drug Treatment Data are included.
- Individuals diagnosed less than 9 months from the end of a given time period are excluded.
- Individuals deceased before by the end of a given time period are excluded.

Data Source: PHSU Reportable HIV Surveillance Data and BCCfE Drug Treatment Data.

VCH48. Proportion of patients who are currently prescribed ARVs

Total alive HIV positive individuals who have a prescription for ARVs in a given time period.

Rationale: A primary objective of the STOP HIV/AIDS program is to ensure that more HIV positive individuals are actively engaged in care and on antiretroviral therapy.

- Numerator: Total number of individuals who have a prescription for ARVs in the last two months of the given time period.
- Denominator: Total alive HIV positive individuals in a given time period.

• Year to Date: take the value from the current half-year and previous half-year.

Additional Selection Criteria:

• Individuals deceased by the end of a given time period are excluded.

Data Source: PHSU Reportable HIV Surveillance Data and BCCfE Drug Treatment Data.

VCH49. Proportion of patients who have discontinued and currently not restarted ARVs

Proportion of alive HIV positive individuals who have not had a prescription for ARVs for at least 2 consecutive months, and not resumed it in the coming month.

Rationale: Not only is it important to ensure that more HIV positive individuals are actively engaged and retained on ARV treatment, it is equally critical for STOP HIV/AIDS pilot project success to reduce the barriers to optimal treatment adherence and the number of people who discontinue ARVs.

Analytical Definition

- Numerator: Number of individuals who have not had a prescription for ARVs for at least 2 consecutive months AND have not resumed taking ARVs during the given time period.
- Denominator: All alive HIV positive individuals who have ever been on ARV treatment.
- Year to Date: take the value from the current half-year and previous half-year.

Additional Selection Criteria:

- The last four month ARV value will be considered in a given time period.
- Records with ARV prescription prior to HIV diagnosis are excluded.
- Individuals deceased by the end of the given time period are excluded.

Data Source: PHSU Reportable HIV Surveillance Data and BCCfE Drug Treatment Data.

VCH51. Proportion of individuals newly taking ARVs who achieve viral suppression within 9 months since treatment starts

Proportion of individuals who are taking ARVs for the first time and who achieve viral suppression within 9 months.

Rationale: Adherence to treatment protocols is essential to reducing the morbidity and mortality associated with HIV and AIDS. The majority of individuals who adhere to ARV treatment protocols achieve virologic suppression, and thus measuring this status serves as a proxy measurement for treatment adherence.

Analytical Definition

- Numerator: A subset of the denominator with having two consecutive viral load record of <200 copies per/mL both taken after therapy start and at least one of which is taken within the first nine months of therapy
- Denominator: All HIV positive individuals initiating first ever ARV treatment in a given time period and who have at least two viral load tests on record.
- Year to Date: take the value from the current half-year and previous half-year.

Additional Selection Criteria:

• This cohort will retrospectively select back over the past 12 months.

- Individuals deceased by the end of the given time period are excluded.
- Individuals with first initiative ARV prescription prior to HIV diagnosis are excluded.
- Viral load testing records that occurred prior to diagnosis date are excluded from this analysis.

Data Source: PHSU Reportable HIV Surveillance Data and BCCfE Drug Treatment Data.

VCH52. Proportion of all individuals on ARVs who currently virally suppressed with viral load less than 200 copies/mL

Proportion of all individuals who are prescribed ARVs and achieved viral suppression.

Rationale: Adherence to treatment protocols is essential to reducing the morbidity and mortality associated with HIV and AIDS. The majority of individuals who adhere to ARV treatment protocols achieve virologic suppression, and thus measuring this status serves as a proxy measurement for treatment adherence. It is important to know the measure of this indicator in both new ARV starts and all individuals on ARV treatment.

Analytical Definition

- Numerator: A subset of the denominator who have two consecutive viral load records of <200 copies per/mL and with at least 3 month apart in the given time period after therapy start.
- Denominator: All HIV positive individuals who were on ARV treatment in a given time period and who have at least 2 viral load tests on record.
- Year to Date: take the value from the current half-year and previous half-year.

Additional Screening Criteria:

- This cohort will retrospectively select back over the past 12 months.
- Individuals deceased by the end of the given time period are excluded.
- Individuals with first initiative ARV prescription prior to HIV diagnosis are excluded.
- Viral load testing records that occurred prior to diagnosis are excluded from this analysis.

Data Source: PHSU Reportable HIV Surveillance Data and BCCfE Drug Treatment Data.

VCH53. Mean monitored viral load of all known HIV positive individuals within VCH

Mean vL values of all HIV positive individuals in the dataset within a given time period.

Rationale: Mean monitored viral load is an indicator of the average viral burden for a particular population of HIV-positive persons, and is related to treatment effectiveness and transmission risk.

Additional Selection Criteria:

- Individuals deceased by the end of the given time period are excluded.
- Viral load testing records with either missing dates or missing values are excluded from this analysis.

Data Source: PHSU Reportable HIV Surveillance Data and BCCfE Drug Treatment Data.

VCH54. Proportion of all individuals with viral load greater than 200 copies/mL

The proportion of HIV positive individuals who have at least a vL tests >200 copies/mL within the given time period.

Rationale: HIV positive individuals with vL levels >200 copies/mL on record are considered to be infective, as opposed to suppressed individuals who are less likely to transmit HIV. This indicator also provides a measure of monitored viral load.

Analytical Definition

- Numerator: A subset of the denominator who have at least a viral load >200 copies/mL within a given time period.
- Denominator: All alive HIV positive individuals in the dataset

Additional Selection Criteria:

- Individuals deceased by the end of the given time period are excluded.
- Viral load testing records with either missing dates or missing values are excluded from this analysis.

Data Source: PHSU Reportable HIV Surveillance Data and BCCfE Drug Treatment Data.

Further Graphs, Maps and Tables

Mean Monitored Viral Load

Rationale: Community viral load is a population-based measure of HIV-infected individual's concentration of plasma HIV-1 RNA (viral load). It is an attractive indicator to monitor the progress of HIV care and treatment when assessed over time. However there is some confusion over the definition and measurement of this indicator. In August of 2011, the US CDC issued a guideline on measurement of community viral load. The document proposed a family of viral load measurements, including population viral load, community viral load, in-care viral load and monitored viral load. In this report, we will use the monitored viral load to track the progress of HIV care and treatment. Monitored Viral Load is limited to the readily observable HIV viral loads of persons who have been diagnosed with HIV infection, who are receiving HIV medical care and disease monitoring through viral load testing, and whose test results are available for surveillance. The guideline also suggests using the most recent viral load result per person for the analysis in the given time period.

Additional Selection Criteria:

- The most recent viral load is used to the analysis in a given time period.
- Individuals deceased by the end of the given time period are excluded.
- Viral load testing records with either missing dates or missing values are excluded from this analysis.

Data Source: PHSU Reportable HIV Surveillance Data and BC CfE Drug Treatment Data.

Appendix B. Population Monitoring Data Sources

HIV Point-of-Care (POC) Data

POC testing volumes reported from VCH sites engaged in STOP HIV/AIDS activities through Vancouver Coastal Health Authority Memorandums of Understanding.

Limitations: This data is not representative of all clinics in Vancouver HSDA or VCH, and thus testing volumes of clinics conducting POC tests outside of STOP HIV/AIDS initiatives are not captured. For this reason, the data likely reflect an underestimate of the true counts for POC testing volumes within the VCH population.

Data on POC preliminary positives, false positives and previous positives is received from VCH CD Control Department. All clinics in VCH who do conduct POC testing report any preliminary positive HIV tests to VCH CD Control Department. VCH CD Control Department conducts follow-up on a reported POC positives to determine if confirmation testing has been completed, and notes any previous and false positives.

Limitations: This process is relatively new, and as a result not all sites conducting POC testing are reporting these data to VCH CD Control Department. For this reason, the data likely reflect an underestimate of the true counts for preliminary positives, false positives and previous positives.

HIV Laboratory Testing Data

Data on HIV laboratory testing volumes is captured from both the PHSA Public Health Microbiology and Reference Laboratory (for all HIV confirmatory western blot analyses in the province of BC) and Providence Health Care (for first-step HIV confirmatory testing for all HIV tests ordered at St. Paul's Hospital).

Limitations: PHSA Public Health Microbiology Reference Laboratory testing data is raw data on all HIV tests conducted within VCH, and analyses were produced using aggregate counts. This data does take into account multiple HIV tests for same sample, but do not take into account multiple HIV tests conducted for an individual within a 30-day period, and thus does not determine test counts by "testing episodes". Data capture for all HIV testing done at St Paul's Hospital was initiated in April 2008, and thus results reported herein for Q1 of 2008 do not include counts done at St. Paul's Hospital.

PHSU Reportable HIV Surveillance Data

Data on all HIV positive tests in VCH is reported to the Public Health Surveillance Unit at Vancouver Coastal Health Authority. This data is captured on a monthly basis, and includes information on sociodemographic characteristics, place of HIV testing, address of residence at time of diagnosis, HIV risk factors and stage of HIV disease at diagnosis. This data does not report on individuals who tested in VCH but are non-residents of VCH.

HIV Clinical Monitoring Data

Clinical monitoring data includes information on viral load (vL) testing information and CD4 testing information that are captured by the BC Centre for Excellence in HIV/AIDS. Viral load data and CD4 data are captured for all HIV positive individuals having such clinical monitoring completed in the province of BC. These data are to be updated in real time, however in some instances there may be small lag times between sample draw date and the time the result ends up in the data base (typically less than 15 days).

Limitations: Real time updates has not always been in place for CD4 values. From 2007 and earlier only annual updates of CD4 measurements were received. Furthermore, all CD4 results are not consistently captured and uploaded into the BC CfE database, as not all sites completing these tests have been linked to source data.

Drug Treatment Program Data

Treatment of nearly all HIV positive individuals in the province of BC is delivered or coordinated through the BC Centre for Excellence Drug Treatment Program. As a result information on treatment regimens, date of treatment starts and restarts is captured for all HIV positive individuals involved in this program.

Limitations: Raw data from the CfE Drug Treatment Program is not provided for these analyses, instead some data have been cleaned and rolled into aggregate counts. As a result, there are some assumptions that have been made in order to work with this data format. These are described in the data definitions.